<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02928224</url>
  </required_header>
  <id_info>
    <org_study_id>ARRAY-818-302</org_study_id>
    <secondary_id>BEACON CRC</secondary_id>
    <secondary_id>2015-005805-35</secondary_id>
    <secondary_id>C4221009</secondary_id>
    <nct_id>NCT02928224</nct_id>
  </id_info>
  <brief_title>Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer</brief_title>
  <acronym>BEACON CRC</acronym>
  <official_title>A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pierre Fabre Medicament</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, open-label, 3-arm Phase 3 study to evaluate encorafenib +&#xD;
      cetuximab plus or minus binimetinib versus Investigator's choice of either&#xD;
      irinotecan/cetuximab or FOLFIRI/cetuximab, as controls, in patients with BRAFV600E mCRC whose&#xD;
      disease has progressed after 1 or 2 prior regimens in the metastatic setting. The study&#xD;
      contains a Safety Lead-in Phase in which the safety and tolerability of encorafenib +&#xD;
      binimetinib + cetuximab will be assessed prior to the Phase 3 portion of the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 13, 2016</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Actual">February 11, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(Safety Lead-in) Number of Participants With Dose-limiting Toxicities (DLTs)</measure>
    <time_frame>Cycle 1 (up to 28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(Safety Lead-in) Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
    <description>Refer to AE/SAE section for additional data that were measured and analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>(Safety Lead-in) Incidence of Dose Interruptions, Dose Modifications and Discontinuations Due to Adverse Events (AEs)</measure>
    <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(Phase 3) Overall Survival (OS) of Triplet Arm vs. Control Arm</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(Phase 3) Response Rate (ORR) by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors (RECIST), v1.1 of Triplet Arm vs. Control Arm</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Response Rate (ORR) by Investigator</measure>
    <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Response Rate (ORR) by BICR</measure>
    <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
    <description>ORR per RECIST, v1.1, defined as the number of patients achieving an overall best response of CR or partial response (PR) divided by the total number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Duration of Response (DOR) by Investigator</measure>
    <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Duration of Response (DOR) by BICR</measure>
    <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
    <description>DOR defined as the time from first radiographic evidence of response to the earliest documented disease progression or death due to underlying disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Time to Response by Investigator</measure>
    <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
    <description>Time to response defined as the time from first dose to first radiographic evidence of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Time to Response by BICR</measure>
    <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
    <description>Time to response defined as the time from first dose to first radiographic evidence of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Progression-free Survival (PFS) by Investigator</measure>
    <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Progression-free Survival (PFS) by BICR</measure>
    <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
    <description>PFS defined as the time from first dose to the earliest documented disease progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Overall Survival (OS) in Doublet Arm vs. Control Arm</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Overall Survival (OS) in Triplet Arm vs. Doublet Arm</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Progression-free Survival (PFS) in Triplet Arm vs Control Arm Per BICR</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Progression-free Survival (PFS) in Triplet Arm vs Control Arm Per Investigator</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Progression-free Survival (PFS) in Doublet Arm vs Control Arm Per BICR</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Progression-free Survival (PFS) in Doublet Arm vs Control Arm Per Investigator</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Progression-free Survival (PFS) in Triplet Arm vs Doublet Arm Per BICR</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Progression-free Survival (PFS) in Triplet Arm vs Doublet Arm Per Investigator</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Control Arm Per Investigator</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Objective Response Rate (ORR) in Doublet Arm vs Control Arm Per BICR</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Objective Response Rate (ORR) in Doublet Arm vs Control Arm Per Investigator</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Doublet Arm Per BICR</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Doublet Arm Per Investigator</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Control Arm Per BICR</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Control Arm Per Investigator</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Duration of Response (DOR) in Doublet Arm vs Control Arm Per BICR</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Duration of Response (DOR) in Doublet Arm vs Control Arm Per Investigator</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Doublet Arm by BICR</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Doublet Arm by Investigator</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Time to Response in Triplet Arm vs Control Arm Per BICR</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Time to Response in Triplet Arm vs Control Arm Per Investigator</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Time to Response in Doublet Arm vs Control Arm Per BICR</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Time to Response in Doublet Arm vs Control Arm Per Investigator</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Time to Response in Triplet Arm vs Doublet Arm Per BICR</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Comparison of Time to Response in Triplet Arm vs Doublet Arm Per Investigator</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Change From Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Cancer Patients (QLQ-C30) Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
    <description>The EORTC QLQ-C30 questionnaire consisted of 30 questions generating five functional scores (physical, role, cognitive, emotional, and social); a global health status/global quality of life scale score; three symptom scale scores (fatigue, pain, and nausea and vomiting); and six stand alone one-item scores that capture additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea) and perceived financial burden. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Change From Baseline in the Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
    <description>FACT-C is a well-characterized and commonly used questionnaire that belongs to the Functional Assessment of Chronic Illness Therapy Measurement System (FACIT). The FACT-G (G for general) questionnaire (27 questions) constitutes the core of all subscales and is applicable to all tumor types. The FACT-C questionnaire contains 9 additional questions on symptoms specific to CRC, 2 of which are only answered by patients with ostomy appliances. These 9 CRC-specific questions are categorized as &quot;additional concerns&quot; on the questionnaire and constitute the &quot;colorectal cancer subscale&quot; score. The patient self-reports his/her QoL for the previous 7 days. The overall score is calculated across all items and a higher score reflects better quality of life (QoL). The table summarizes the functional well-being subscale, the individual questions are linearly scaled and combined to form the functional well-being subscale score, which ranges from 0-28 (higher is better QoL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Change From Baseline in the EuroQol-5D-5L (EQ-5D-5L) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
    <description>The EQ-5D-5L contains 1 item for each of 5 dimensions of health-related QoL (i.e., mobility, self-care, usual activities, pain or discomfort and anxiety or depression). Response options for each item varied from having no problems to moderate problems or extreme problems. The EQ-5D-5L (v4.0) is a standardized measure of health utility that provides a single index value for one's health status. The EQ-5D-5L is frequently used for economic evaluations of health care and has been recognized as a valid and reliable instrument for this purpose. The EQ visual analog scale (VAS) is a score that is directly reported by the patient and ranges from 0 to 100 (higher is better quality health).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Change From Baseline in the Patient Global Impression of Change (PGIC) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet</measure>
    <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
    <description>The PGIC is a measure of patients' perceptions of change in their symptoms over time that can be used as an anchoring method to determine the minimal clinically important difference for other patient reported outcome (PROs). For this assessment, patients answered the following question: &quot;Since starting treatment, my colorectal cancer symptoms are: (1) very much improved, (2) much improved, (3) minimally improved, (4) no change, (5) minimally worse, (6) much worse or (7) very much worse.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the Area Under the Concentration-time Curve (AUC) for Cetuximab</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the Area Under the Concentration-time Curve (AUC) for Encorafenib</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the Area Under the Concentration-time Curve (AUC) for Binimetinib</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the Area Under the Concentration-time Curve (AUC) for Metabolite of Binimetinib (AR00426032)</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Cetuximab</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Encorafenib</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Binimetinib</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Metabolite of Binimetinib (AR00426032)</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Cetuximab</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Encorafenib</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Binimetinib</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Metabolite of Binimetinib (AR00426032)</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the Steady-state Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for Binimetinib</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the Steady-state Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for Encorafenib</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the Steady-state Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for Cetuximab</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Safety Lead-in) Evaluation of the Steady-state Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for a Metabolite of Binimetinib</measure>
    <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Evaluation of the Model-Based Oral Clearance (CL/F) for Encorafenib</measure>
    <time_frame>2 and 6 hours post-dose on Day 1 of Cycle 1. Predose and 2 hours post-dose on Day 1 of Cycle 2.</time_frame>
    <description>The cross-arm CL/F value is based on the theta determined from a population PK analysis. Data for this Outcome Measure are not reported here because as per plan, the analysis includes pooled data from participants enrolled in multiple studies including those who were not enrolled in this study. The NCTID for those studies for which results have not yet been posted include: NCT01719380, NCT01543698, and NCT01436656. An additional study ARRAY-162-105 is not required to register.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Evaluation of the Model-Based Oral Clearance (CL/F) for Binimetinib</measure>
    <time_frame>2 and 6 hours post-dose on Day 1 of Cycle 1. Predose and 2 hours post-dose on Day 1 of Cycle 2.</time_frame>
    <description>The cross-arm CL/F value is based on the theta determined from a population PK analysis. Data for this Outcome Measure are not reported here because as per plan, the analysis includes pooled data from participants enrolled in multiple studies including those who were not enrolled in this study. The NCTID for those studies for which results have not yet been posted include: NCT01719380, NCT01543698, and NCT01436656. An additional study ARRAY-162-105 is not required to register.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Phase 3) Evaluation of the Model-Based Clearance (CL) for Cetuximab</measure>
    <time_frame>2 and 6 hours post-dose on Day 1 of Cycle 1. Predose and 2 hours post-dose on Day 1 of Cycle 2.</time_frame>
    <description>The cross-arm CL/F value is based on the theta determined from a population PK analysis. Data for this Outcome Measure are not reported here because as per plan, the analysis includes pooled data from participants enrolled in multiple studies including those who were not enrolled in this study. The NCTID for those studies for which results have not yet been posted include: NCT01719380, NCT01543698, and NCT01436656. An additional study ARRAY-162-105 is not required to register.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">702</enrollment>
  <condition>BRAF V600E-mutant Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Safety Lead-in, Triplet Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Encorafenib + binimetinib + cetuximab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doublet Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Encorafenib + cetuximab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Encorafenib</intervention_name>
    <description>Orally, once daily.</description>
    <arm_group_label>Doublet Arm</arm_group_label>
    <arm_group_label>Safety Lead-in, Triplet Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Binimetinib</intervention_name>
    <description>Orally, twice daily.</description>
    <arm_group_label>Safety Lead-in, Triplet Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Standard of care.</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Doublet Arm</arm_group_label>
    <arm_group_label>Safety Lead-in, Triplet Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Standard of care.</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folinic Acid</intervention_name>
    <description>Standard of care.</description>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>FA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil</intervention_name>
    <description>Standard of care.</description>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>5-FU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years at time of informed consent&#xD;
&#xD;
          -  Histologically- or cytologically-confirmed CRC that is metastatic&#xD;
&#xD;
          -  Presence of BRAFV600E in tumor tissue as previously determined by a local assay at any&#xD;
             time prior to Screening or by the central laboratory&#xD;
&#xD;
          -  Progression of disease after 1 or 2 prior regimens in the metastatic setting&#xD;
&#xD;
          -  Evidence of measurable or evaluable non-measurable disease per RECIST, v1.1&#xD;
&#xD;
          -  Adequate bone marrow, cardiac, kidney and liver function&#xD;
&#xD;
          -  Able to take oral medications&#xD;
&#xD;
          -  Female patients are either postmenopausal for at least 1 year, are surgically sterile&#xD;
             for at least 6 weeks, or must agree to take appropriate precautions to avoid pregnancy&#xD;
             from screening through follow-up if of childbearing potential&#xD;
&#xD;
          -  Males must agree to take appropriate precautions to avoid fathering a child from&#xD;
             screening through follow-up&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with any RAF inhibitor, MEK inhibitor, cetuximab, panitumumab or other&#xD;
             epidermal growth factor receptor (EGFR) inhibitors&#xD;
&#xD;
          -  Prior irinotecan hypersensitivity or toxicity that would suggest an inability to&#xD;
             tolerate irinotecan 180 mg/m2 every 2 weeks&#xD;
&#xD;
          -  Symptomatic brain metastasis or leptomeningeal disease&#xD;
&#xD;
          -  History or current evidence of retinal vein occlusion or current risk factors for&#xD;
             retinal vein occlusion (e.g., uncontrolled glaucoma or ocular hypertension, history of&#xD;
             hyperviscosity or hypercoagulability syndromes)&#xD;
&#xD;
          -  Known history of acute or chronic pancreatitis&#xD;
&#xD;
          -  History of chronic inflammatory bowel disease or Crohn's disease requiring medical&#xD;
             intervention (immunomodulatory or immunosuppressive medications or surgery) ≤12 months&#xD;
             prior to randomization&#xD;
&#xD;
          -  Uncontrolled blood pressure despite medical treatment&#xD;
&#xD;
          -  Impaired GI function or disease that may significantly alter the absorption of&#xD;
             encorafenib or binimetinib (e.g., ulcerative diseases, uncontrolled vomiting,&#xD;
             malabsorption syndrome, small bowel resection with decreased intestinal absorption)&#xD;
&#xD;
          -  Concurrent or previous other malignancy within 5 years of study entry, except cured&#xD;
             basal or squamous cell skin cancer, superficial bladder cancer, prostate&#xD;
             intraepithelial neoplasm, carcinoma in-situ of the cervix, or other noninvasive or&#xD;
             indolent malignancy&#xD;
&#xD;
          -  History of thromboembolic or cerebrovascular events ≤ 6 months prior to starting study&#xD;
             treatment, including transient ischemic attacks, cerebrovascular accidents, deep vein&#xD;
             thrombosis or pulmonary emboli&#xD;
&#xD;
          -  Concurrent neuromuscular disorder that is associated with the potential of elevated&#xD;
             creatine (phosphor)kinase (CK) (e.g., inflammatory myopathies, muscular dystrophy,&#xD;
             amyotrophic lateral sclerosis, spinal muscular atrophy)&#xD;
&#xD;
          -  Residual common terminology criteria for adverse events (CTCAE) ≥ Grade 2 toxicity&#xD;
             from any prior anticancer therapy, with the exception of Grade 2 alopecia or Grade 2&#xD;
             neuropathy&#xD;
&#xD;
          -  Known history of HIV infection&#xD;
&#xD;
          -  Active hepatitis B or hepatitis C infection&#xD;
&#xD;
          -  Known history of Gilbert's syndrome&#xD;
&#xD;
          -  Known contraindication to receive cetuximab or irinotecan at the planned doses&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope (City of Hope National Medical Center, City of Hope Medical Center)</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compassionate Care Research Group, Inc. at Compassionate Cancer Care Medical Group, Inc.</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keck Hospital of USC - Norris Healthcare Center (HC3)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keck Hospital of USC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LAC+USC Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norris Healthcare Center 3 (HC3)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC Eye Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harvard Eye Associates</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Lions Eye Institute</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center - Anschutz Cancer Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver CTO (CTRC)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital Inpatient Pavillion'</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Yale - New Haven</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple Medical Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University, Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital Care Center at North Haven</name>
      <address>
        <city>North Haven</city>
        <state>Connecticut</state>
        <zip>06473</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Lennar Foundation Medical Center</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Broward Health Medical Center</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Clayton Berger (opthalmology)</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mehmet F. Hepgur, MD - Broward Health Medical Center</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bascon Palmer Eye Institue</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center/UMHC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sylvester at Kendall</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare- Bloomington</name>
      <address>
        <city>Bloomington</city>
        <state>Illinois</state>
        <zip>61704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare- Galesburg</name>
      <address>
        <city>Galesburg</city>
        <state>Illinois</state>
        <zip>61401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center at Silver Cross Hospital</name>
      <address>
        <city>New Lenox</city>
        <state>Illinois</state>
        <zip>60451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medicine Center for Advanced Care Orland Park</name>
      <address>
        <city>Orland Park</city>
        <state>Illinois</state>
        <zip>60462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare- Ottawa</name>
      <address>
        <city>Ottawa</city>
        <state>Illinois</state>
        <zip>61350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Care, PC</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois Eye Center</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Drug Services IUHSCC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney &amp;Lois Eskenazi Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IU Health Springmill</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Health Floyd Cancer Center</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Clinical Research Center</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KU Eye</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <zip>66208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Cancer Center and Medical Pavilion</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Cancer Center, Investigational Drug Services</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Investigational Drug Pharmacy (IDS) in the Sidney Kimmel Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Boston Inc</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute (DFCI)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center - West County</name>
      <address>
        <city>Creve Coeur</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SSM Health Saint Louis University Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnes Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SSM Health Saint Louis University Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Infusion Center Pharmacy</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center - South County</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center - St Peters</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63376</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering: Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering: Rockefeller Outpatient Pavilion</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Institute</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Casey Eye Institute-South Waterfront</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OHSU Center for Health and Healing</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OHSU Research Pharmacy Services</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry-Joyce Cancer Clinic</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Eye Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott &amp; White Clinic - Temple Pavilion</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott &amp; White Medical Center - Temple</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates, PS DBA Summit Cancer Centers</name>
      <address>
        <city>Spokane Valley</city>
        <state>Washington</state>
        <zip>99216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spokane Eye Clinic</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inland Imaging, LLC Holy Family Hospital</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates, PS DBA Summit Cancer Centers</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Holy Family Nuclear Medicine</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Clinical Science Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CLINICA PERGAMINO S.A. (Centro de Investigacion Pergamino S.A.)</name>
      <address>
        <city>Pergamino</city>
        <state>Buenos Aires</state>
        <zip>2700</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico INFINITO</name>
      <address>
        <city>Santa Rosa</city>
        <state>LA Pampa</state>
        <zip>L6300EAN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico CAIPO (Centro para la Atención del paciente Oncológico)</name>
      <address>
        <city>San Miguel de Tucumán</city>
        <state>Tucumán</state>
        <zip>T4000GTB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria Reina Fabiola</name>
      <address>
        <city>Cordoba</city>
        <zip>X5004FHP</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Riojano Integral - CORI</name>
      <address>
        <city>La Rioja</city>
        <zip>5300</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Clinic</name>
      <address>
        <city>Darlinghurst</city>
        <state>NEW South Wales (nsw)</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Sydney</name>
      <address>
        <city>Darlinghurst</city>
        <state>NEW South Wales (nsw)</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marsden Eye Specialists</name>
      <address>
        <city>Parramatta</city>
        <state>NEW South Wales (nsw)</state>
        <zip>2150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle Eye Centre</name>
      <address>
        <city>Sydney</city>
        <state>NEW South Wales (nsw)</state>
        <zip>2300</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae Limited</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Adelaide Local Health Network Inc. operating as Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Adelaide Local Health Network Inc. operating as The Queen Elizabeth Hospital</name>
      <address>
        <city>Woodville South</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Health Translation Precinct - Monash Health</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels - Grieskirchen GmbH, Abteilung fuer Innere Medizin IV</name>
      <address>
        <city>Wels</city>
        <state>Oberoesterreich</state>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen GmbH, Abteilung fuer Augenheilkunde und Optometrie</name>
      <address>
        <city>Wels</city>
        <state>Oberoesterreich</state>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen GmbH, Abteilung fuer Innere Medizin II</name>
      <address>
        <city>Wels</city>
        <state>Oberoesterreich</state>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen GmbH, Apotheke</name>
      <address>
        <city>Wels</city>
        <state>Oberoesterreich</state>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen GmbH, Institut fuer Nuklearmedizin</name>
      <address>
        <city>Wels</city>
        <state>Oberoesterreich</state>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen GmbH, Institut fuer Radiologie I</name>
      <address>
        <city>Wels</city>
        <state>Oberoesterreich</state>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DZU, Diagnose Zentrum Urania GmbH</name>
      <address>
        <city>Wien</city>
        <zip>1010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitaet Wien/AKH Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien/AKH Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Ardenne - Site de Libramont</name>
      <address>
        <city>Libramont-Chevigny</city>
        <state>Luxembourg</state>
        <zip>6800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan Brugge - Oostende AV - Campus Sint-Jan - Oncology</name>
      <address>
        <city>Brugge</city>
        <state>WEST Vlaanderen</state>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imelda Ziekenhuis</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand Hopital de Charleroi (GHdC)</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Maria Middelares</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Gasthuisberg (UZ Leuven)</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire (CHU) de Liege</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHC Saint Joseph</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Delta Roeselaere-Menen</name>
      <address>
        <city>Roeselaere</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional (CHR) - Verviers</name>
      <address>
        <city>Verviers</city>
        <zip>4800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital do Hlho</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>41820-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CENOB - Centro de Oncologia da Bahia SS Ltda / Oncovida</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>41820-021</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEMES Centro Medico Especializado em Oftalmologia</name>
      <address>
        <city>Cachoeiro de Itapemirim</city>
        <state>ES</state>
        <zip>29300-045</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisas Clínicas em Oncologia</name>
      <address>
        <city>Cachoeiro de Itapemirim</city>
        <state>ES</state>
        <zip>29308-014</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Evangelico de Cachoeiro de Itapemirim</name>
      <address>
        <city>Cachoeiro de Itapemirim</city>
        <state>ES</state>
        <zip>29308-055</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Vizibelli</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30110-921</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CENANTRON - Centro Avancado de Tratamento Oncologic</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30130-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundação Universidade de Caxias do Sul</name>
      <address>
        <city>Caxias do Sul</city>
        <state>RS</state>
        <zip>95070-560</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daniel Lubisco Pandolfi</name>
      <address>
        <city>Lajeado</city>
        <state>RS</state>
        <zip>95900-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sociedade Beneficencia e Cardade de Lajeado/Hospital Bruno Born</name>
      <address>
        <city>Lajeado</city>
        <state>RS</state>
        <zip>95900-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sociedade Beneficencia e Cardade de Lajeado/Hospital Bruno Born</name>
      <address>
        <city>Lajeado</city>
        <state>RS</state>
        <zip>95900-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associacao Hospitalar Beneficente Sao Vicente de Paulo / Hospital Sao Vicente de Paulo</name>
      <address>
        <city>Passo Fundo</city>
        <state>RS</state>
        <zip>99010-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultorio Medico de Oftalmologia - Dr. Ricardo Tres</name>
      <address>
        <city>Passo Fundo</city>
        <state>RS</state>
        <zip>99010-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Vicente de Paulo</name>
      <address>
        <city>Passo Fundo</city>
        <state>RS</state>
        <zip>99010-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thiago Vernetti Ferreira</name>
      <address>
        <city>Pelotas</city>
        <state>RS</state>
        <zip>96010-140</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leandro Becker</name>
      <address>
        <city>Pelotas</city>
        <state>RS</state>
        <zip>96015-280</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fernanda Mendes</name>
      <address>
        <city>Pelotas</city>
        <state>RS</state>
        <zip>96020-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPCO - Unidade de Pesquisas Clinicas em Oncologia</name>
      <address>
        <city>Pelotas</city>
        <state>RS</state>
        <zip>96020-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fernanda Lauermann</name>
      <address>
        <city>Pelotas</city>
        <state>RS</state>
        <zip>96020-260</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diogo Duarte Torre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90020-013</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Farmacia Central da Irmandade da Santa Casa de Misericordia de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90020-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irmandade da Santa Casa de Misericordia de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90020-090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nucleo de Novos Tratamentos em Cancer</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90050-170</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa Clínica de Oncologia e Hematologia - Hospital Mãe de Deus/AESC</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90110-270</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica de Oftalmologia Lavinsky</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90470-340</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mãe de Deus</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90880-480</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Toller</name>
      <address>
        <city>Barretos</city>
        <state>SAO Paulo</state>
        <zip>14780-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olhos Centro Diagnostico e Laser LTDA</name>
      <address>
        <city>Barretos</city>
        <state>SAO Paulo</state>
        <zip>14780-300</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacao Pio XII</name>
      <address>
        <city>Barretos</city>
        <state>SAO Paulo</state>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Giuliano Santos Borges - ME / Clinica de Neoplasias Litoral - Centro de Novos Tratamentos Itajai</name>
      <address>
        <city>Itajai</city>
        <state>SC</state>
        <zip>88301-220</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FUNDAÇÃO DO ABC - Faculdade de Medicina do ABC</name>
      <address>
        <city>Santo Andre</city>
        <state>SP</state>
        <zip>09060-650</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FUNDAÇÃO DO ABC - Faculdade de Medicina do ABC</name>
      <address>
        <city>Santo Andre</city>
        <state>SP</state>
        <zip>09060-870</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto</name>
      <address>
        <city>Sao Jose do Rio Preto</city>
        <state>SP</state>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEPOS - Centro de Estudos e Pesquisas Oncologicas de Sorocaba</name>
      <address>
        <city>Sorocaba</city>
        <state>SP</state>
        <zip>18030-075</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Oncologia de Sorocaba &quot;Dr. Gilson Delgado&quot;</name>
      <address>
        <city>Sorocaba</city>
        <state>SP</state>
        <zip>18030-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karen Miyuki Kubokawa Shorer</name>
      <address>
        <city>Sorocaba</city>
        <state>SP</state>
        <zip>18040-425</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oftalmologia Diagnostica de Sorocaba (ODS)</name>
      <address>
        <city>Sorocaba</city>
        <state>SP</state>
        <zip>18047-620</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Ensino e Pesquisa São Lucas</name>
      <address>
        <city>São Paulo</city>
        <zip>01236-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Ensino e Pesquisa São Lucas - Pharmacy</name>
      <address>
        <city>São Paulo</city>
        <zip>01242-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Leforte</name>
      <address>
        <city>São Paulo</city>
        <zip>01507-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPEPO - Instituto da Visao</name>
      <address>
        <city>São Paulo</city>
        <zip>04038-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Care Centre, Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 3N9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BC Cancer, Vancouver Center</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Research Institute</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre integre universitaire de sante et de services sociaux de l'Ouest-de-l'Ile-de-Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Clinico Oncologico del Sur (ICOS)</name>
      <address>
        <city>Temuco</city>
        <state>Region DE LA Araucania</state>
        <zip>4810469</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Vina Del Mar</name>
      <address>
        <city>Vina del Mar</city>
        <state>V Region Valparaiso</state>
        <zip>2520612</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ocni ordinace Oftalpro s.r.o.</name>
      <address>
        <city>Brno</city>
        <zip>603 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Masarykuv onkologicky ustav</name>
      <address>
        <city>Brno</city>
        <zip>656 53</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fingerlanduv ustav patologie</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I. interni kardioangiologicka klinika</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika nemoci koznich a pohlavnich</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnicni lekarna - Usek klinickych studii</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ocni klinika</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiologicka klinika</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomouc, I. interni klinika - kardiologicka</name>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomouc, Lekarna</name>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital (OUH)</name>
      <address>
        <city>Odense C</city>
        <zip>DK-5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Jean Minjoz</name>
      <address>
        <city>Besancon Cedex</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Morvan</name>
      <address>
        <city>BREST Cedex</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Ophtalmologique - Pole Vision - Clinique Val d'Ouest</name>
      <address>
        <city>Ecully</city>
        <zip>69130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon Cedex 08</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICM Val d'Aurelle</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU HOTEL-Dieu</name>
      <address>
        <city>Nantes Cedex</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier national d'ophtalmologie des Quinze-Vingts</name>
      <address>
        <city>Paris Cedex 12</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier National d'Opthalmologie des Quinze-Vingts (CHNO des XV-XX)</name>
      <address>
        <city>Paris Cedex 12</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Robert Debre</name>
      <address>
        <city>Reims Cedex</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCM Centre d'ophtalmologie</name>
      <address>
        <city>Saint Jeand De Vedas</city>
        <zip>34430</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse-Institut Inuversitaire du Cancer Toulouse</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse-Rangueil</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse - Purpan, hopital Pierre-Paul Riquet</name>
      <address>
        <city>Toulouse</city>
        <zip>31057</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden-wuerttemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-wuerttemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augenklinik der Universitaet Muenchen</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU Klinikum der Universitaet Muenchen, Campus Grosshadern</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augenarzt-Gemeinschaftspraxis Dr.med.Andreas Kind &amp; Dr.med. Ute Kariger-Schweigert</name>
      <address>
        <city>Falkensee</city>
        <state>Brandenburg</state>
        <zip>14612</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover (MHH)</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen Mitte / Knappschaftskrankenhaus</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-westfalen</state>
        <zip>35136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis fuer Augenheilkunde Dr. Edmund Meyer-Schwickerath</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-westfalen</state>
        <zip>45131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen-Mitte</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-westfalen</state>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen (AoeR), Innere Klinik (Tumorforschung), Westdeutsches Tumorzentrum</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-westfalen</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen; Diagnostischeu. Interventionelle Radiologie u. Neuroradiologie</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-westfalen</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen; Nuklearmedizin</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-westfalen</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen; Zentralapotheke</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-westfalen</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evang. Krankenhaus Essen - Werden; Klinik fuer Augenheilkunde</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-westfalen</state>
        <zip>45239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen Mitte / Knappschaftskrankenhaus</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-westfalen</state>
        <zip>45276</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augentagesklinik Maria-Hilf Krankenhaus</name>
      <address>
        <city>Moenchengladbach</city>
        <state>Nordrhein-westfalen</state>
        <zip>41063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Maria Hilf GmbH - Franziskuskrankenhaus</name>
      <address>
        <city>Moenchengladbach</city>
        <state>Nordrhein-westfalen</state>
        <zip>41063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Maria Hilf GmbH; Klinik fuer Radiologie</name>
      <address>
        <city>Moenchengladbach</city>
        <state>Nordrhein-westfalen</state>
        <zip>41063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lukaskrankenhaus Neuss; Zentrale Apotheke</name>
      <address>
        <city>Neuss</city>
        <state>Nordrhein-westfalen</state>
        <zip>41464</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut f. Pathologie - Ruhr-Universitaet Bochum, Prof. Dr. med. Andrea Tannapfel</name>
      <address>
        <city>Bochum</city>
        <state>North Rhine Westfalia</state>
        <zip>44789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augenarzt Praxis Dr. med. Petra Huelsmann</name>
      <address>
        <city>Worms</city>
        <state>Rheinland-pfalz</state>
        <zip>67547</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis fuer Radiologie und Nuklearmedizin, Standort Worms</name>
      <address>
        <city>Worms</city>
        <state>Rheinland-pfalz</state>
        <zip>67547</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin Apotheke</name>
      <address>
        <city>Worms</city>
        <state>Rheinland-pfalz</state>
        <zip>67547</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Worms</name>
      <address>
        <city>Worms</city>
        <state>Rheinland-pfalz</state>
        <zip>67547</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxisgemeinschaft Kruse + Hofstaetter</name>
      <address>
        <city>Worms</city>
        <state>Rheinland-pfalz</state>
        <zip>67547</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Waldkrankenhaus Spandau</name>
      <address>
        <city>Berlin</city>
        <zip>13589</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Carl Gustav Carus der Technischen Universitaet Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Hamburg Eppendorf, Klinik fuer Augenheilkunde</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Facharztzentrum Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Hamburg Eppendorf, Zentrum fuer Radiologie und Endoskopie</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZytoService Deutschland GmbH, Standort-Hamburg-Jenfeld</name>
      <address>
        <city>Hamburg</city>
        <zip>22045</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HKS Kardiologische Praxis am Israelitischen Krankenhaus</name>
      <address>
        <city>Hamburg</city>
        <zip>22297</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiologie im Israelitischen Krankenhaus</name>
      <address>
        <city>Hamburg</city>
        <zip>22297</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zala Megyei Szent Rafael Korhaz - Onkologiai Osztaly</name>
      <address>
        <city>Zalaegerszeg</city>
        <state>Zala</state>
        <zip>H-8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent Margit Kórház</name>
      <address>
        <city>Budapest</city>
        <zip>1032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magyar Honvedseg Egeszsegugyi Kozpont</name>
      <address>
        <city>Budapest</city>
        <zip>1062</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Egyesitett Szent Istvan es Szent Laszlo Korhaz-Rendelointezet</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uzsoki Utcai Korhaz</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar</name>
      <address>
        <city>Pecs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pecsi Tudomanyegyetem Klinikai Kozpont</name>
      <address>
        <city>Pecs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center - Oncology</name>
      <address>
        <city>Tel-Aviv</city>
        <state>NAP</state>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Barzilai Medical Center - Oncology Institute</name>
      <address>
        <city>Ashkelon</city>
        <zip>7830604</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka University Medical Center</name>
      <address>
        <city>Be'er-Sheva</city>
        <zip>8410101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MOR Institute</name>
      <address>
        <city>Bnei Brak</city>
        <zip>5126413</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ein-Karem Department of Medical Imaging of Hadassah Medical Organization, Hadassah Medical Center,</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Organization, Hadassah Medical Center, Ein-Karem</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmacy of Hadassah Medical Organization, Hadassah Medical Center, Ein-Karem</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Scopus Department of Medical Imaging of Hadassah Medical Organization,</name>
      <address>
        <city>Jerusalem</city>
        <zip>91240</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imaging Department of Meir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmacy of Meir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmacy of Rabin Medical Center, Beilinson Hospital</name>
      <address>
        <city>Petah Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center, Beilinson Hospital</name>
      <address>
        <city>Petah Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Chaim Sheba Medical Center</name>
      <address>
        <city>Tel-Hashomer</city>
        <zip>5262100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti Umberto I</name>
      <address>
        <city>Torrette Di Ancona</city>
        <state>Ancona</state>
        <zip>60020</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Bergamo Ovest, Ospedale Treviglio Caravaggio di Trevigl</name>
      <address>
        <city>Treviglio</city>
        <state>Bergamo</state>
        <zip>24047</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Farmacia - ASST Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oculistica, ASST Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncologia, ASST Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica di Oncologia Medica AOU di Cagliari Presidio Duilio Casula Monserrato</name>
      <address>
        <city>Monserrato</city>
        <state>Cagliari</state>
        <zip>09042</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Farmacia AOU di Cagliari Presidio Duilio Casula Monserrato</name>
      <address>
        <city>Monserrato</city>
        <state>Cagliari</state>
        <zip>09042</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiologia AOU di Cagliari Presidio Duilio Casula Monserrato</name>
      <address>
        <city>Monserrato</city>
        <state>Cagliari</state>
        <zip>09042</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oculistica - ASST Cremona, Ospedale di Cremona</name>
      <address>
        <city>Cremona</city>
        <state>CR</state>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Farmacia Aziendale - ASST Cremona, Ospedale di Cremona</name>
      <address>
        <city>Cremona</city>
        <state>CR</state>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Oncologia - ASST Cremona, Ospedale di Cremona</name>
      <address>
        <city>Cremona</city>
        <state>CR</state>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Oculistica, Istituto Clinico HUMANITAS</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. di Oncologia ed Ematologia, Istituto Clinico HUMANITAS</name>
      <address>
        <city>Rozzano (MI)</city>
        <state>Milan</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale San Raffaele - U.O. di Medicina Oncologica</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servizio di Farmacia - IRCCS Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Radiologia diagnostica e interventistica - Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Farmacia - Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Oncologia Medica 1, SS Oncologia Medica Gastroenterologica</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiologia per i pazienti oncologici - Istituto Oncologico Veneto I.R.C.C.S</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Oculistica - Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servizio Farmacia - Istituto Oncologico Veneto I.R.C.C.S</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Oncologia Medica 1 - Istituto Oncologico Veneto I.R.C.C.S</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico S.Orsola Malpighi, AOU di Bologna - Oncologia Medica</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione Anatomia Patologica Presidio San Giovanni di Dio</name>
      <address>
        <city>Cagliari</city>
        <zip>09124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oculistica AOU di Cagliari Presidio San Giovanni di Dio</name>
      <address>
        <city>Cagliari</city>
        <zip>09124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Careggi - Oncologia Medica 1</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC oncologia Medica I - Azienda Ospedaliero Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiologia</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servizio Farmacia Ospedaliera</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unita di Oncologia Medica Gastrointestinale e Tumori Neuroendocrini</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grande Ospedale Metropolitano Niguarda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento Interaziendale Farmaceutico - AOU Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC di Oftalmologia - AOU Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC di Radiologia, Dipartimento Interaziendale integrato Diagnostica per Immagini</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SSD Day Hospital Oncologico - Dipartimento ad attivita integrata di Oncologia, Ematologia</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Universita degli Studi della Campania L. Vanvitelli - DAI di Medicina Interna e Specialistica</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Universita degli Studi della Campania L. Vanvitelli - U. Ma.Ca.</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Universita degli Studi della Campania L. Vanvitelli</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Universita degli Studi della Campania L. Vanvitelli</name>
      <address>
        <city>Napoli</city>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Oculistica - AOU Pisana, Stabilimento Ospedaliero di Cisanello</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SOD Radiodiagnostica 3 - AOU Pisana, Stabilimento Ospedaliero di Santa Chiara</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Farmaceutica, Gestione del Farmaco - AOU Pisana, Stabilimento Ospedaliero di Santa Chiara</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Oncologia Medica 2 - AOU Pisana, Stabilimento Ospedaliero di Santa Chiara</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. Farmacia Clinica - Fondazione PTV Policlinico Tor Vergata</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.S.D. Oncologia Medica, Dipartimento di Medicina - Fondazione PTV Policlinico Tor Vergata</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.S.D. Patologie Retiniche - Fondazione PTV Policlinico Tor Vergata</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chayagasaka Eye Clinic</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>464-0092</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanazawa University Hospital</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <zip>920-8641</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marianna University School of Medicine Hospital</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <zip>216-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tsukahara Eye Clinic</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>241-0821</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cancer Center</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>241-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital Laboratory for Clinical Investigation</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Cancer Center</name>
      <address>
        <city>Fukuoka</city>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers</name>
      <address>
        <city>Fukuoka</city>
        <zip>815-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Osaka National Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>540-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggi-do</state>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Anyang</city>
        <state>Gyeonggido</state>
        <zip>14068</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun-gun</city>
        <state>Jeollanam-do</state>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49201</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Superare Centro de Infusion S.A. de C.V.</name>
      <address>
        <city>Delegacion Cuauhtemoc</city>
        <state>Ciudad DE Mexico</state>
        <zip>06760</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultorio dentro de la Torre Medica Dalinde (Oncologia Medica)</name>
      <address>
        <city>Ciudad de Mexico</city>
        <state>Cuauhtemoc</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rijnstate Hospital Arnhem</name>
      <address>
        <city>Arnhem</city>
        <state>Gelderland</state>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rijnstate Hospital Velp</name>
      <address>
        <city>Velp</city>
        <state>Gelderland</state>
        <zip>6883 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center (MUMC)</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-holland</state>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwen Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-holland</state>
        <zip>1091 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haga Ziekenhuis</name>
      <address>
        <city>Den Haag</city>
        <state>Zuid-holland</state>
        <zip>2545 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colosseum Øyelegesenter C/O LB Holdings AS</name>
      <address>
        <city>Lommedalen</city>
        <zip>1350</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colosseum Øyelegesenter C/O LB Holdings AS</name>
      <address>
        <city>Oslo</city>
        <zip>0369</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo universitetssykehus, Radiumhospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>0379</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sykehusapoteket Oslo, Radiumhospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>0379</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Specjalistyczny W Brzozowie, Podkarpacki Osrodek Onkologiczny Im.Ks.B.Markiewicza</name>
      <address>
        <city>Brzozow</city>
        <zip>36-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Zespolony, Oddzial Onkologiczny</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Specjalistyczny im. L. Rydygiera w Krakowie Sp.z.o.o.</name>
      <address>
        <city>Krakow</city>
        <zip>31-826</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Europejskie Centrum Zdrowia Otwock, Szpital im. F. Chopina</name>
      <address>
        <city>Otwock</city>
        <zip>05-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Centrum Medyczne HCP</name>
      <address>
        <city>Poznan</city>
        <zip>61-485</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Przychodnia Specjalistyczna GUTMED</name>
      <address>
        <city>Poznan</city>
        <zip>61495</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne MAVIT Sp. z o.o.</name>
      <address>
        <city>Warszawa</city>
        <zip>01-673</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAGODENT Sp. z o.o. Szpital Elblaska</name>
      <address>
        <city>Warszawa</city>
        <zip>01-748</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magodent Sp. z o.o., Przychodnia Specjalistyczna i Rehabilitacja, Poradnia Okulistyczna</name>
      <address>
        <city>Warszawa</city>
        <zip>02-524</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAGODENT Sp. z o.o. Szpital Onkologiczny, Oddzial Onkologii Klinicznej i Chemioterapii</name>
      <address>
        <city>Warszawa</city>
        <zip>03-291</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magodent Sp. z o.o., Szpital Onkologiczno-Kardiologiczny, Dzial Farmacji Szpitalnej</name>
      <address>
        <city>Warszawa</city>
        <zip>04-125</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Budgetary Healthcare Institution Kursk Regional Clinical</name>
      <address>
        <city>Kursk</city>
        <state>Kursk Region</state>
        <zip>305524</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evimed Llc</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454048</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budget Institution &quot;N.N. Blokhin Russian Cancer Research Center&quot; of the</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budget Institution &quot;N.N. Blokhin Russian Cancer Research Center&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A. Tsyb Medical Radiological Research Center - branch of the</name>
      <address>
        <city>Obninsk</city>
        <zip>249036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Educational Institution of Higher Professional Education First Saint Petersburg</name>
      <address>
        <city>Sankt-Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaen</name>
      <address>
        <city>Jaen</city>
        <state>Andalucia</state>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sercosa - Clinica de las Nieves</name>
      <address>
        <city>Jaen</city>
        <state>Andalucia</state>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Baleares</state>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Cordoba</city>
        <state>Cordona</state>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nuestra Señora del Rosario</name>
      <address>
        <city>Madrid</city>
        <state>Madrid, Communidad Delaware</state>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Sant Joan de Reus</name>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <zip>43204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Corachan</name>
      <address>
        <city>Barcelona</city>
        <zip>08017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Quiron Salud Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08023</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cetir Centre Medic S.L.</name>
      <address>
        <city>Barcelona</city>
        <zip>08029</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Burgos</name>
      <address>
        <city>Burgos</city>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consulta Dr. Juan Carlos Castillo Dominguez</name>
      <address>
        <city>Cordoba</city>
        <zip>14008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabinete Radiologico Dr. Pita</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital HM Universitario Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Oftalvist</name>
      <address>
        <city>Valencia</city>
        <zip>46004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Instituto Valenciano de Oncologia</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Quiron Salud Zaragoza</name>
      <address>
        <city>Zaragoza</city>
        <zip>50006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Changhua city</city>
        <state>Changhua County</state>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital, Linkou</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege University Medical Faculty</name>
      <address>
        <city>Izmir</city>
        <state>Bornova</state>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Izmir Medical Park Hospital - Medical Oncology</name>
      <address>
        <city>Izmir</city>
        <state>Izmir, Karsiyaka</state>
        <zip>35575</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul Medeniyet University Göztepe Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <state>Kadikoy</state>
        <zip>34722</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe University Medical Faculty</name>
      <address>
        <city>Ankara</city>
        <zip>06230</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uludag University Medical Faculty</name>
      <address>
        <city>Bursa</city>
        <zip>16059</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trakya Universitesi Tip Fakultesi</name>
      <address>
        <city>Edirne</city>
        <zip>22030</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inonu Universitesi Turgut Ozal Medical Center</name>
      <address>
        <city>Malatya</city>
        <zip>44280</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oftalmolohycheskyi tsentr &quot;Vzghliad&quot; MTs</name>
      <address>
        <city>Dnipropetrovsk</city>
        <state>Dnipropetrovska Oblast'</state>
        <zip>41100</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oftalmolohycheskyi tsentr &quot;Vzghliad&quot; MTs</name>
      <address>
        <city>Dnipropetrovsk</city>
        <state>Dnipropetrovska Oblast'</state>
        <zip>49027</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derzhavnyi zaklad, Dnipropetrovska medychna akademiia Ministerstva okhorony zdorovia Ukrainy</name>
      <address>
        <city>Dnipropetrovsk</city>
        <state>Dnipropetrovska Oblast'</state>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Komumalnyi zaklad, Dnipropetrovska miska bahatoprofilna klinichna likarnia Nº4</name>
      <address>
        <city>Dnipropetrovsk</city>
        <state>Dnipropetrovska Oblast'</state>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyivska klinichna likarnia na zaliznychnomu transporti No3 filii Tsentr okhorony zdorov'ia PAT</name>
      <address>
        <city>Kyiv</city>
        <state>Kyivska Oblast'</state>
        <zip>02096</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Natsionalnyi medychnyi universytet imeni O.O Bohomltsia, kafedra onkolohii</name>
      <address>
        <city>Kyiv</city>
        <state>Kyivska Oblast'</state>
        <zip>02096</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Natsionalnyi medychnyi universytet imeni O.O Bohomltsia, kafedra oftalmolohii</name>
      <address>
        <city>Kyiv</city>
        <state>Kyivska Oblast</state>
        <zip>01601</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oleksandrivska klinichna likarnia mista Kyieva</name>
      <address>
        <city>Kyiv</city>
        <state>Kyivska Oblast</state>
        <zip>01601</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyivskyi miskyi klinichnyi onkotsentr</name>
      <address>
        <city>Kyiv</city>
        <state>Kyivska Oblast</state>
        <zip>03115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinnytskyi oblasnyi klinichnyi onkolohichnyi dyspanser, viddilennia khimioterapii</name>
      <address>
        <city>Vinnytsia</city>
        <state>Vinnyts'ka Oblast'</state>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DVNZ &quot;Uzhhorodskyi natsionalnyi universytet&quot;</name>
      <address>
        <city>Uzhgorod</city>
        <state>Zakarpats'ka Oblast'</state>
        <zip>88000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tsentralna miska klinichna likarnia, Miskyi onkolohichnyi tsentr</name>
      <address>
        <city>Uzhgorod</city>
        <state>Zakarpats'ka Oblast'</state>
        <zip>88000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DVNZ &quot;Uzhhorodskyi natsionalnyi universytet&quot;</name>
      <address>
        <city>Uzhhorod</city>
        <state>Zakarpatska Oblast</state>
        <zip>88000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TOV &quot;Zakarpatskyi Tsentr Mikrokhirurhii Oka&quot;</name>
      <address>
        <city>Uzhhorod</city>
        <state>Zakarpatska Oblast</state>
        <zip>88000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Grampian - Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <state>Aberdeenshire Scotland</state>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Edward V11 Hospital</name>
      <address>
        <city>Windsor</city>
        <state>Berkshire</state>
        <zip>SL4 3DP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasglow</city>
        <state>Glasglow City, Scotland</state>
        <zip>G12 0YH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>WEST Midlands</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital, Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust, Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute UK</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust, Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust - Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=ARRAY-818-302</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 16, 2016</study_first_submitted>
  <study_first_submitted_qc>October 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2016</study_first_posted>
  <results_first_submitted>May 6, 2020</results_first_submitted>
  <results_first_submitted_qc>June 19, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 14, 2020</results_first_posted>
  <disposition_first_submitted>December 19, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>December 19, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">December 20, 2019</disposition_first_posted>
  <last_update_submitted>November 6, 2021</last_update_submitted>
  <last_update_submitted_qc>November 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal cancer</keyword>
  <keyword>BRAF</keyword>
  <keyword>BRAFV600E</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 11, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT02928224/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 28, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT02928224/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were at least 18 years of age with confirmed metastatic colorectal cancer (CRC) whose disease had progressed after 1 or 2 prior regimens in the metastatic setting and whose tumor tissue was BRAF V600E-mutant as previously determined by a local assay at any time prior to Screening</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Combined Safety Lead-in</title>
          <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
        </group>
        <group group_id="P2">
          <title>Phase 3: Triplet Arm</title>
          <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
        </group>
        <group group_id="P3">
          <title>Phase 3: Doublet Arm</title>
          <description>Encorafenib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Cetuximab: Standard of care.</description>
        </group>
        <group group_id="P4">
          <title>Phase 3:Control Arm</title>
          <description>Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.&#xD;
Cetuximab: Standard of care.&#xD;
Irinotecan: Standard of care.&#xD;
Folinic Acid: Standard of care.&#xD;
5-Fluorouracil: Standard of care.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="224"/>
                <participants group_id="P3" count="220"/>
                <participants group_id="P4" count="221"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="224"/>
                <participants group_id="P3" count="220"/>
                <participants group_id="P4" count="221"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Randomized, Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="78"/>
                <participants group_id="P3" count="78"/>
                <participants group_id="P4" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="104"/>
                <participants group_id="P3" count="101"/>
                <participants group_id="P4" count="103"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Changes in Patient's Condition</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Dose Interruptions&gt;28</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Decision to Discontinue Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not listed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline analysis population consists of the Full Analysis Set (FAS). For patients in the CSLI, the FAS includes all patients who received at least 1 dose of study drug and had at least 1 post treatment assessment, which may include death. For the randomized Phase 3 portion of the study, the FAS consists of all randomized patients.</population>
      <group_list>
        <group group_id="B1">
          <title>Combined Safety Lead-in (CSLI)</title>
          <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
        </group>
        <group group_id="B2">
          <title>Phase 3: Triplet Arm</title>
          <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
        </group>
        <group group_id="B3">
          <title>Phase 3: Doublet Arm</title>
          <description>Encorafenib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Cetuximab: Standard of care.</description>
        </group>
        <group group_id="B4">
          <title>Phase 3:Control Arm</title>
          <description>Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.&#xD;
Cetuximab: Standard of care.&#xD;
Irinotecan: Standard of care.&#xD;
Folinic Acid: Standard of care.&#xD;
5-Fluorouracil: Standard of care.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
            <count group_id="B2" value="224"/>
            <count group_id="B3" value="220"/>
            <count group_id="B4" value="221"/>
            <count group_id="B5" value="702"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="141"/>
                    <measurement group_id="B3" value="137"/>
                    <measurement group_id="B4" value="149"/>
                    <measurement group_id="B5" value="450"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="72"/>
                    <measurement group_id="B5" value="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.3" spread="10.34"/>
                    <measurement group_id="B2" value="59.5" spread="11.65"/>
                    <measurement group_id="B3" value="60.2" spread="11.65"/>
                    <measurement group_id="B4" value="58.4" spread="12.07"/>
                    <measurement group_id="B5" value="59.3" spread="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="105"/>
                    <measurement group_id="B4" value="127"/>
                    <measurement group_id="B5" value="373"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="115"/>
                    <measurement group_id="B4" value="94"/>
                    <measurement group_id="B5" value="329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="195"/>
                    <measurement group_id="B3" value="183"/>
                    <measurement group_id="B4" value="172"/>
                    <measurement group_id="B5" value="579"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>North America</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="92"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Europe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="145"/>
                    <measurement group_id="B4" value="125"/>
                    <measurement group_id="B5" value="445"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rest of World (includes Mexico)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="67"/>
                    <measurement group_id="B5" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group Performance Status (ECOG PS) at Baseline</title>
          <description>ECOG PS was used to assess the physical health of patients, and ranges from 0 (most active) to 5 (dead). Frequency counts and percentages of patients in each score category were provided by treatment arm and assessment visit.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0-Fully active</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="112"/>
                    <measurement group_id="B4" value="108"/>
                    <measurement group_id="B5" value="358"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1-Restircted in physically strenuous activity</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="104"/>
                    <measurement group_id="B4" value="113"/>
                    <measurement group_id="B5" value="340"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2-Ambulatory and capable of all self-care</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Tumor Location</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Left Colon</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="68"/>
                    <measurement group_id="B5" value="241"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Right Colon</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="110"/>
                    <measurement group_id="B4" value="119"/>
                    <measurement group_id="B5" value="378"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Left and Right Colon</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary Tumor Removed</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Completely Resected</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="123"/>
                    <measurement group_id="B4" value="122"/>
                    <measurement group_id="B5" value="398"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partially Resected/Unresected</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="97"/>
                    <measurement group_id="B4" value="99"/>
                    <measurement group_id="B5" value="304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Organs Involved</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&gt;=2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="117"/>
                    <measurement group_id="B4" value="123"/>
                    <measurement group_id="B5" value="370"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="98"/>
                    <measurement group_id="B5" value="332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sites of Metastases</title>
          <units>sites</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Liver</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="134"/>
                    <measurement group_id="B4" value="128"/>
                    <measurement group_id="B5" value="430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="86"/>
                    <measurement group_id="B5" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph Node</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="88"/>
                    <measurement group_id="B5" value="273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NodePeritoneum/Omentum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="97"/>
                    <measurement group_id="B4" value="93"/>
                    <measurement group_id="B5" value="284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>(Safety Lead-in) Number of Participants With Dose-limiting Toxicities (DLTs)</title>
        <time_frame>Cycle 1 (up to 28 days)</time_frame>
        <population>The Dose-determining Set (DDS) consisted of all CSLI patients from the Safety Set who either completed a minimum exposure requirement (received ≥ 75% dose intensity of the planned dose for each binimetinib, encorafenib and cetuximab) and had sufficient safety evaluations or experienced a dose-limiting toxicity (DLT).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in (CSLI)</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Number of Participants With Dose-limiting Toxicities (DLTs)</title>
          <population>The Dose-determining Set (DDS) consisted of all CSLI patients from the Safety Set who either completed a minimum exposure requirement (received ≥ 75% dose intensity of the planned dose for each binimetinib, encorafenib and cetuximab) and had sufficient safety evaluations or experienced a dose-limiting toxicity (DLT).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>(Safety Lead-in) Number of Participants With Adverse Events (AEs)</title>
        <description>Refer to AE/SAE section for additional data that were measured and analyzed.</description>
        <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Safety Set consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. Patients were analyzed according to treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Number of Participants With Adverse Events (AEs)</title>
          <description>Refer to AE/SAE section for additional data that were measured and analyzed.</description>
          <population>The Safety Set consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. Patients were analyzed according to treatment received.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>(Safety Lead-in) Incidence of Dose Interruptions, Dose Modifications and Discontinuations Due to Adverse Events (AEs)</title>
        <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Safety Set consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. Patients were analyzed according to treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Incidence of Dose Interruptions, Dose Modifications and Discontinuations Due to Adverse Events (AEs)</title>
          <population>The Safety Set consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. Patients were analyzed according to treatment received.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>(Phase 3) Overall Survival (OS) of Triplet Arm vs. Control Arm</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.&#xD;
Cetuximab: Standard of care.&#xD;
Irinotecan: Standard of care.&#xD;
Folinic Acid: Standard of care.&#xD;
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Overall Survival (OS) of Triplet Arm vs. Control Arm</title>
          <population>The Full Analysis Set (FAS) for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.03" lower_limit="8.02" upper_limit="11.43"/>
                    <measurement group_id="O2" value="5.42" lower_limit="4.76" upper_limit="6.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>(Phase 3) Response Rate (ORR) by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors (RECIST), v1.1 of Triplet Arm vs. Control Arm</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Phase 3 Response Efficacy Set consisted of the first 330 patients randomized into the Phase 3 portion of the study and any additional patients randomized on the same day as the 330th randomized patient.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.&#xD;
Cetuximab: Standard of care.&#xD;
Irinotecan: Standard of care.&#xD;
Folinic Acid: Standard of care.&#xD;
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Response Rate (ORR) by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors (RECIST), v1.1 of Triplet Arm vs. Control Arm</title>
          <population>The Phase 3 Response Efficacy Set consisted of the first 330 patients randomized into the Phase 3 portion of the study and any additional patients randomized on the same day as the 330th randomized patient.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="18.2" upper_limit="35.3"/>
                    <measurement group_id="O2" value="2" lower_limit=".2" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Response Rate (ORR) by Investigator</title>
        <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Safety Lead-in (SLI) Efficacy Set consisted of all CSLI patients in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Response Rate (ORR) by Investigator</title>
          <population>The Safety Lead-in (SLI) Efficacy Set consisted of all CSLI patients in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.8" lower_limit="35.5" upper_limit="69.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Response Rate (ORR) by BICR</title>
        <description>ORR per RECIST, v1.1, defined as the number of patients achieving an overall best response of CR or partial response (PR) divided by the total number of patients</description>
        <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The SLI Efficacy Set consisted of all CSLI patients in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Response Rate (ORR) by BICR</title>
          <description>ORR per RECIST, v1.1, defined as the number of patients achieving an overall best response of CR or partial response (PR) divided by the total number of patients</description>
          <population>The SLI Efficacy Set consisted of all CSLI patients in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7" lower_limit="25.5" upper_limit="59.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Duration of Response (DOR) by Investigator</title>
        <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The SLI Efficacy Set consisted of all CSLI patients in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Duration of Response (DOR) by Investigator</title>
          <population>The SLI Efficacy Set consisted of all CSLI patients in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.47" lower_limit="4.17" upper_limit="11.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Duration of Response (DOR) by BICR</title>
        <description>DOR defined as the time from first radiographic evidence of response to the earliest documented disease progression or death due to underlying disease</description>
        <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The SLI Efficacy Set consisted of all CSLI patients in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Duration of Response (DOR) by BICR</title>
          <description>DOR defined as the time from first radiographic evidence of response to the earliest documented disease progression or death due to underlying disease</description>
          <population>The SLI Efficacy Set consisted of all CSLI patients in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.15" lower_limit="2.79" upper_limit="NA">NA= not reached. Insufficient number of participants with events to calculate the upper limit of the 95% confidence interval.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Time to Response by Investigator</title>
        <description>Time to response defined as the time from first dose to first radiographic evidence of response</description>
        <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The SLI Efficacy Set consisted of all CSLI patients in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Time to Response by Investigator</title>
          <description>Time to response defined as the time from first dose to first radiographic evidence of response</description>
          <population>The SLI Efficacy Set consisted of all CSLI patients in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" lower_limit="1.38" upper_limit="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Time to Response by BICR</title>
        <description>Time to response defined as the time from first dose to first radiographic evidence of response</description>
        <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The SLI Efficacy Set consisted of all CSLI patients in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Time to Response by BICR</title>
          <description>Time to response defined as the time from first dose to first radiographic evidence of response</description>
          <population>The SLI Efficacy Set consisted of all CSLI patients in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" lower_limit="1.38" upper_limit="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Progression-free Survival (PFS) by Investigator</title>
        <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The SLI Efficacy Set consisted of all CSLI patients in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Progression-free Survival (PFS) by Investigator</title>
          <population>The SLI Efficacy Set consisted of all CSLI patients in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.08" lower_limit="5.59" upper_limit="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Progression-free Survival (PFS) by BICR</title>
        <description>PFS defined as the time from first dose to the earliest documented disease progression or death due to any cause</description>
        <time_frame>Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The SLI Efficacy Set consisted of all CSLI patients in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Progression-free Survival (PFS) by BICR</title>
          <description>PFS defined as the time from first dose to the earliest documented disease progression or death due to any cause</description>
          <population>The SLI Efficacy Set consisted of all CSLI patients in the FAS who were identified at screening as having a BRAF V600E mutation (per local or central testing).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.59" lower_limit="4.44" upper_limit="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Overall Survival (OS) in Doublet Arm vs. Control Arm</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Doublet Arm</title>
            <description>Encorafenib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.&#xD;
Cetuximab: Standard of care.&#xD;
Irinotecan: Standard of care.&#xD;
Folinic Acid: Standard of care.&#xD;
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Overall Survival (OS) in Doublet Arm vs. Control Arm</title>
          <population>The Full Analysis Set (FAS) for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.41" lower_limit="7.46" upper_limit="11.04"/>
                    <measurement group_id="O2" value="5.42" lower_limit="4.76" upper_limit="6.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Overall Survival (OS) in Triplet Arm vs. Doublet Arm</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3: Doublet Arm</title>
            <description>Encorafenib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Overall Survival (OS) in Triplet Arm vs. Doublet Arm</title>
          <population>The Full Analysis Set (FAS) for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.03" lower_limit="8.02" upper_limit="11.43"/>
                    <measurement group_id="O2" value="8.41" lower_limit="7.46" upper_limit="11.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Progression-free Survival (PFS) in Triplet Arm vs Control Arm Per BICR</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.&#xD;
Cetuximab: Standard of care.&#xD;
Irinotecan: Standard of care.&#xD;
Folinic Acid: Standard of care.&#xD;
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Progression-free Survival (PFS) in Triplet Arm vs Control Arm Per BICR</title>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.30" lower_limit="4.14" upper_limit="5.19"/>
                    <measurement group_id="O2" value="1.51" lower_limit="1.45" upper_limit="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Progression-free Survival (PFS) in Triplet Arm vs Control Arm Per Investigator</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.&#xD;
Cetuximab: Standard of care.&#xD;
Irinotecan: Standard of care.&#xD;
Folinic Acid: Standard of care.&#xD;
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Progression-free Survival (PFS) in Triplet Arm vs Control Arm Per Investigator</title>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.47" lower_limit="4.24" upper_limit="5.36"/>
                    <measurement group_id="O2" value="1.58" lower_limit="1.51" upper_limit="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Progression-free Survival (PFS) in Doublet Arm vs Control Arm Per BICR</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Doublet Arm</title>
            <description>Encorafenib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.&#xD;
Cetuximab: Standard of care.&#xD;
Irinotecan: Standard of care.&#xD;
Folinic Acid: Standard of care.&#xD;
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Progression-free Survival (PFS) in Doublet Arm vs Control Arm Per BICR</title>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.21" lower_limit="3.71" upper_limit="5.36"/>
                    <measurement group_id="O2" value="1.51" lower_limit="1.45" upper_limit="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Progression-free Survival (PFS) in Doublet Arm vs Control Arm Per Investigator</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Doublet Arm</title>
            <description>Encorafenib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.&#xD;
Cetuximab: Standard of care.&#xD;
Irinotecan: Standard of care.&#xD;
Folinic Acid: Standard of care.&#xD;
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Progression-free Survival (PFS) in Doublet Arm vs Control Arm Per Investigator</title>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.27" lower_limit="4.04" upper_limit="5.36"/>
                    <measurement group_id="O2" value="1.58" lower_limit="1.51" upper_limit="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Progression-free Survival (PFS) in Triplet Arm vs Doublet Arm Per BICR</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3: Doublet Arm</title>
            <description>Encorafenib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Progression-free Survival (PFS) in Triplet Arm vs Doublet Arm Per BICR</title>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.30" lower_limit="4.14" upper_limit="5.19"/>
                    <measurement group_id="O2" value="4.21" lower_limit="3.71" upper_limit="5.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Progression-free Survival (PFS) in Triplet Arm vs Doublet Arm Per Investigator</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3: Doublet Arm</title>
            <description>Encorafenib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Progression-free Survival (PFS) in Triplet Arm vs Doublet Arm Per Investigator</title>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.47" lower_limit="4.24" upper_limit="5.36"/>
                    <measurement group_id="O2" value="4.27" lower_limit="4.04" upper_limit="5.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Control Arm Per Investigator</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.&#xD;
Cetuximab: Standard of care.&#xD;
Irinotecan: Standard of care.&#xD;
Folinic Acid: Standard of care.&#xD;
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Control Arm Per Investigator</title>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Objective Response Rate (ORR) in Doublet Arm vs Control Arm Per BICR</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Phase 3 Response Efficacy Set consisted of the first 330 patients randomized into the Phase 3 portion of the study and any additional patients randomized on the same day as the 330th randomized patient.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Doublet Arm</title>
            <description>Encorafenib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.&#xD;
Cetuximab: Standard of care.&#xD;
Irinotecan: Standard of care.&#xD;
Folinic Acid: Standard of care.&#xD;
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Objective Response Rate (ORR) in Doublet Arm vs Control Arm Per BICR</title>
          <population>The Phase 3 Response Efficacy Set consisted of the first 330 patients randomized into the Phase 3 portion of the study and any additional patients randomized on the same day as the 330th randomized patient.</population>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="13.4" upper_limit="29"/>
                    <measurement group_id="O2" value="2" lower_limit=".2" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Objective Response Rate (ORR) in Doublet Arm vs Control Arm Per Investigator</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Phase 3 Response Efficacy Set consisted of the first 330 patients randomized into the Phase 3 portion of the study and any additional patients randomized on the same day as the 330th randomized patient.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Doublet Arm</title>
            <description>Encorafenib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.&#xD;
Cetuximab: Standard of care.&#xD;
Irinotecan: Standard of care.&#xD;
Folinic Acid: Standard of care.&#xD;
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Objective Response Rate (ORR) in Doublet Arm vs Control Arm Per Investigator</title>
          <population>The Phase 3 Response Efficacy Set consisted of the first 330 patients randomized into the Phase 3 portion of the study and any additional patients randomized on the same day as the 330th randomized patient.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="220"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Doublet Arm Per BICR</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Phase 3 Response Efficacy Set consisted of the first 330 patients randomized into the Phase 3 portion of the study and any additional patients randomized on the same day as the 330th randomized patient.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3: Doublet Arm</title>
            <description>Encorafenib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Doublet Arm Per BICR</title>
          <population>The Phase 3 Response Efficacy Set consisted of the first 330 patients randomized into the Phase 3 portion of the study and any additional patients randomized on the same day as the 330th randomized patient.</population>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="18.2" upper_limit="35.3"/>
                    <measurement group_id="O2" value="23" lower_limit="13.4" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Doublet Arm Per Investigator</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Phase 3 Response Efficacy Set consisted of the first 330 patients randomized into the Phase 3 portion of the study and any additional patients randomized on the same day as the 330th randomized patient.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3: Doublet Arm</title>
            <description>Encorafenib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Doublet Arm Per Investigator</title>
          <population>The Phase 3 Response Efficacy Set consisted of the first 330 patients randomized into the Phase 3 portion of the study and any additional patients randomized on the same day as the 330th randomized patient.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Control Arm Per BICR</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.&#xD;
Cetuximab: Standard of care.&#xD;
Irinotecan: Standard of care.&#xD;
Folinic Acid: Standard of care.&#xD;
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Control Arm Per BICR</title>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.80" lower_limit="2.96" upper_limit="9.69"/>
                    <measurement group_id="O2" value="NA" lower_limit="2.56" upper_limit="NA">NA= not reached. Insufficient number of participants with events to calculate the upper limit of the 95% confidence interval.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Control Arm Per Investigator</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.&#xD;
Cetuximab: Standard of care.&#xD;
Irinotecan: Standard of care.&#xD;
Folinic Acid: Standard of care.&#xD;
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Control Arm Per Investigator</title>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.80" lower_limit="3.29" upper_limit="6.57"/>
                    <measurement group_id="O2" value="5.75" lower_limit="2.56" upper_limit="NA">NA= not reached. Insufficient number of participants with events to calculate the upper limit of the 95% confidence interval.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Duration of Response (DOR) in Doublet Arm vs Control Arm Per BICR</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Doublet Arm</title>
            <description>Encorafenib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.&#xD;
Cetuximab: Standard of care.&#xD;
Irinotecan: Standard of care.&#xD;
Folinic Acid: Standard of care.&#xD;
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Duration of Response (DOR) in Doublet Arm vs Control Arm Per BICR</title>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.06" lower_limit="4.07" upper_limit="8.28"/>
                    <measurement group_id="O2" value="NA" lower_limit="2.56" upper_limit="NA">NA= not reached. Insufficient number of participants with events to calculate the upper limit of the 95% confidence interval.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Duration of Response (DOR) in Doublet Arm vs Control Arm Per Investigator</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Doublet Arm</title>
            <description>Encorafenib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.&#xD;
Cetuximab: Standard of care.&#xD;
Irinotecan: Standard of care.&#xD;
Folinic Acid: Standard of care.&#xD;
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Duration of Response (DOR) in Doublet Arm vs Control Arm Per Investigator</title>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.70" lower_limit="3.65" upper_limit="6.74"/>
                    <measurement group_id="O2" value="5.75" lower_limit="2.56" upper_limit="NA">NA= not reached. Insufficient number of participants with events to calculate the upper limit of the 95% confidence interval.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Doublet Arm by BICR</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Phase 3 Response Efficacy Set consisted of the first 330 patients randomized into the Phase 3 portion of the study and any additional patients randomized on the same day as the 330th randomized patient.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Doublet Arm</title>
            <description>Encorafenib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Doublet Arm by BICR</title>
          <population>The Phase 3 Response Efficacy Set consisted of the first 330 patients randomized into the Phase 3 portion of the study and any additional patients randomized on the same day as the 330th randomized patient.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.80" lower_limit="2.96" upper_limit="9.69"/>
                    <measurement group_id="O2" value="6.06" lower_limit="4.07" upper_limit="8.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Doublet Arm by Investigator</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Phase 3 Response Efficacy Set consisted of the first 330 patients randomized into the Phase 3 portion of the study and any additional patients randomized on the same day as the 330th randomized patient.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Doublet Arm</title>
            <description>Encorafenib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Doublet Arm by Investigator</title>
          <population>The Phase 3 Response Efficacy Set consisted of the first 330 patients randomized into the Phase 3 portion of the study and any additional patients randomized on the same day as the 330th randomized patient.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.80" lower_limit="3.29" upper_limit="6.57"/>
                    <measurement group_id="O2" value="5.70" lower_limit="3.65" upper_limit="6.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Time to Response in Triplet Arm vs Control Arm Per BICR</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.&#xD;
Cetuximab: Standard of care.&#xD;
Irinotecan: Standard of care.&#xD;
Folinic Acid: Standard of care.&#xD;
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Time to Response in Triplet Arm vs Control Arm Per BICR</title>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" lower_limit="1.41" upper_limit="1.51"/>
                    <measurement group_id="O2" value="1.45" lower_limit="1.41" upper_limit="2.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Time to Response in Triplet Arm vs Control Arm Per Investigator</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.&#xD;
Cetuximab: Standard of care.&#xD;
Irinotecan: Standard of care.&#xD;
Folinic Acid: Standard of care.&#xD;
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Time to Response in Triplet Arm vs Control Arm Per Investigator</title>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" lower_limit="1.41" upper_limit="1.51"/>
                    <measurement group_id="O2" value="2.63" lower_limit="1.45" upper_limit="2.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Time to Response in Doublet Arm vs Control Arm Per BICR</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Doublet Arm</title>
            <description>Encorafenib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.&#xD;
Cetuximab: Standard of care.&#xD;
Irinotecan: Standard of care.&#xD;
Folinic Acid: Standard of care.&#xD;
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Time to Response in Doublet Arm vs Control Arm Per BICR</title>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" lower_limit="1.41" upper_limit="1.58"/>
                    <measurement group_id="O2" value="1.45" lower_limit="1.41" upper_limit="2.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Time to Response in Doublet Arm vs Control Arm Per Investigator</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Doublet Arm</title>
            <description>Encorafenib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Control Arm</title>
            <description>Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.&#xD;
Cetuximab: Standard of care.&#xD;
Irinotecan: Standard of care.&#xD;
Folinic Acid: Standard of care.&#xD;
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Time to Response in Doublet Arm vs Control Arm Per Investigator</title>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" lower_limit="1.41" upper_limit="1.54"/>
                    <measurement group_id="O2" value="2.63" lower_limit="1.45" upper_limit="2.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Time to Response in Triplet Arm vs Doublet Arm Per BICR</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Doublet Arm</title>
            <description>Encorafenib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Time to Response in Triplet Arm vs Doublet Arm Per BICR</title>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" lower_limit="1.41" upper_limit="1.51"/>
                    <measurement group_id="O2" value="1.48" lower_limit="1.41" upper_limit="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Comparison of Time to Response in Triplet Arm vs Doublet Arm Per Investigator</title>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Doublet Arm</title>
            <description>Encorafenib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Comparison of Time to Response in Triplet Arm vs Doublet Arm Per Investigator</title>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" lower_limit="1.41" upper_limit="1.51"/>
                    <measurement group_id="O2" value="1.48" lower_limit="1.41" upper_limit="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Change From Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Cancer Patients (QLQ-C30) Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet</title>
        <description>The EORTC QLQ-C30 questionnaire consisted of 30 questions generating five functional scores (physical, role, cognitive, emotional, and social); a global health status/global quality of life scale score; three symptom scale scores (fatigue, pain, and nausea and vomiting); and six stand alone one-item scores that capture additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea) and perceived financial burden. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning.</description>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Doublet Arm</title>
            <description>Encorafenib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O3">
            <title>Phase 3:Control Arm</title>
            <description>Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.&#xD;
Cetuximab: Standard of care.&#xD;
Irinotecan: Standard of care.&#xD;
Folinic Acid: Standard of care.&#xD;
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Change From Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Cancer Patients (QLQ-C30) Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet</title>
          <description>The EORTC QLQ-C30 questionnaire consisted of 30 questions generating five functional scores (physical, role, cognitive, emotional, and social); a global health status/global quality of life scale score; three symptom scale scores (fatigue, pain, and nausea and vomiting); and six stand alone one-item scores that capture additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea) and perceived financial burden. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning.</description>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="209"/>
                    <count group_id="O2" value="201"/>
                    <count group_id="O3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.8" spread="22.18"/>
                    <measurement group_id="O2" value="60.7" spread="21.33"/>
                    <measurement group_id="O3" value="62.8" spread="21.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="138"/>
                    <count group_id="O2" value="133"/>
                    <count group_id="O3" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="13.44"/>
                    <measurement group_id="O2" value="-4.3" spread="16.27"/>
                    <measurement group_id="O3" value="-3.4" spread="15.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="181"/>
                    <count group_id="O2" value="180"/>
                    <count group_id="O3" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="19.06"/>
                    <measurement group_id="O2" value="3.8" spread="18.46"/>
                    <measurement group_id="O3" value="-1.9" spread="22.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="18.86"/>
                    <measurement group_id="O2" value="3.5" spread="19.96"/>
                    <measurement group_id="O3" value="-0.2" spread="24.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="105"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="15.63"/>
                    <measurement group_id="O2" value="4.2" spread="22.17"/>
                    <measurement group_id="O3" value="1.4" spread="21.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="99"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="18.66"/>
                    <measurement group_id="O2" value="4.3" spread="22.09"/>
                    <measurement group_id="O3" value="-2.2" spread="22.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="16.76"/>
                    <measurement group_id="O2" value="5.6" spread="23.25"/>
                    <measurement group_id="O3" value="-4.5" spread="19.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="16.01"/>
                    <measurement group_id="O2" value="4.3" spread="21.77"/>
                    <measurement group_id="O3" value="1.7" spread="12.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="14.83"/>
                    <measurement group_id="O2" value="4.2" spread="16.98"/>
                    <measurement group_id="O3" value="0.0" spread="27.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.8" spread="17.74"/>
                    <measurement group_id="O2" value="-5.6" spread="16.44"/>
                    <measurement group_id="O3" value="-4.8" spread="12.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="17.90"/>
                    <measurement group_id="O2" value="-2.8" spread="16.97"/>
                    <measurement group_id="O3" value="2.1" spread="20.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 11 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="20.38"/>
                    <measurement group_id="O2" value="3.9" spread="15.31"/>
                    <measurement group_id="O3" value="33.3" spread="NA">Number analyzed is 1 so standard deviation (SD) is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 12 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="22.41"/>
                    <measurement group_id="O2" value="-4.6" spread="13.77"/>
                    <measurement group_id="O3" value="4.2" spread="53.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="20.41"/>
                    <measurement group_id="O2" value="-3.2" spread="14.25"/>
                    <measurement group_id="O3" value="0.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 14 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="24.26"/>
                    <measurement group_id="O2" value="-6.0" spread="15.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 15 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="33.63"/>
                    <measurement group_id="O2" value="2.8" spread="8.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.7" spread="42.08"/>
                    <measurement group_id="O2" value="-5.6" spread="9.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 17 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.8" spread="20.97"/>
                    <measurement group_id="O2" value="-2.8" spread="12.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 18 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.7" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                    <measurement group_id="O2" value="-8.3" spread="8.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 19 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                    <measurement group_id="O2" value="-8.3" spread="11.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 20 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                    <measurement group_id="O2" value="-8" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 21 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                    <measurement group_id="O2" value="-16.7" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 22 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-16.7" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 23 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.1" spread="22.66"/>
                    <measurement group_id="O2" value="-13.1" spread="21.61"/>
                    <measurement group_id="O3" value="-15.5" spread="27.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Day Follow Up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.4" spread="22.51"/>
                    <measurement group_id="O2" value="-10.4" spread="15.96"/>
                    <measurement group_id="O3" value="-24.6" spread="24.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Change From Baseline in the Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet</title>
        <description>FACT-C is a well-characterized and commonly used questionnaire that belongs to the Functional Assessment of Chronic Illness Therapy Measurement System (FACIT). The FACT-G (G for general) questionnaire (27 questions) constitutes the core of all subscales and is applicable to all tumor types. The FACT-C questionnaire contains 9 additional questions on symptoms specific to CRC, 2 of which are only answered by patients with ostomy appliances. These 9 CRC-specific questions are categorized as &quot;additional concerns&quot; on the questionnaire and constitute the &quot;colorectal cancer subscale&quot; score. The patient self-reports his/her QoL for the previous 7 days. The overall score is calculated across all items and a higher score reflects better quality of life (QoL). The table summarizes the functional well-being subscale, the individual questions are linearly scaled and combined to form the functional well-being subscale score, which ranges from 0-28 (higher is better QoL).</description>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Doublet Arm</title>
            <description>Encorafenib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O3">
            <title>Phase 3:Control Arm</title>
            <description>Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.&#xD;
Cetuximab: Standard of care.&#xD;
Irinotecan: Standard of care.&#xD;
Folinic Acid: Standard of care.&#xD;
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Change From Baseline in the Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet</title>
          <description>FACT-C is a well-characterized and commonly used questionnaire that belongs to the Functional Assessment of Chronic Illness Therapy Measurement System (FACIT). The FACT-G (G for general) questionnaire (27 questions) constitutes the core of all subscales and is applicable to all tumor types. The FACT-C questionnaire contains 9 additional questions on symptoms specific to CRC, 2 of which are only answered by patients with ostomy appliances. These 9 CRC-specific questions are categorized as &quot;additional concerns&quot; on the questionnaire and constitute the &quot;colorectal cancer subscale&quot; score. The patient self-reports his/her QoL for the previous 7 days. The overall score is calculated across all items and a higher score reflects better quality of life (QoL). The table summarizes the functional well-being subscale, the individual questions are linearly scaled and combined to form the functional well-being subscale score, which ranges from 0-28 (higher is better QoL).</description>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="211"/>
                    <count group_id="O2" value="199"/>
                    <count group_id="O3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" spread="6.22"/>
                    <measurement group_id="O2" value="16.2" spread="5.9"/>
                    <measurement group_id="O3" value="16.8" spread="6.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                    <count group_id="O2" value="130"/>
                    <count group_id="O3" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="3.36"/>
                    <measurement group_id="O2" value="-0.9" spread="4.06"/>
                    <measurement group_id="O3" value="-1.4" spread="3.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="183"/>
                    <count group_id="O2" value="176"/>
                    <count group_id="O3" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="4.28"/>
                    <measurement group_id="O2" value="-0.6" spread="5.08"/>
                    <measurement group_id="O3" value="-0.9" spread="4.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="137"/>
                    <count group_id="O3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="5.15"/>
                    <measurement group_id="O2" value="-0.2" spread="5.23"/>
                    <measurement group_id="O3" value="-0.7" spread="5.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="119"/>
                    <count group_id="O2" value="105"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="4.53"/>
                    <measurement group_id="O2" value="-0.1" spread="4.66"/>
                    <measurement group_id="O3" value="-1.8" spread="6.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="6.4"/>
                    <measurement group_id="O2" value="-0.2" spread="4.5"/>
                    <measurement group_id="O3" value="-1.6" spread="4.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="6.05"/>
                    <measurement group_id="O2" value="0.6" spread="4.56"/>
                    <measurement group_id="O3" value="-1.9" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="5.85"/>
                    <measurement group_id="O2" value="-0.1" spread="4.70"/>
                    <measurement group_id="O3" value="-0.5" spread="5.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="6.35"/>
                    <measurement group_id="O2" value="0.2" spread="4.24"/>
                    <measurement group_id="O3" value="-2.1" spread="4.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="4.32"/>
                    <measurement group_id="O2" value="-0.8" spread="3.74"/>
                    <measurement group_id="O3" value="-2.6" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="4.76"/>
                    <measurement group_id="O2" value="-1.3" spread="3.59"/>
                    <measurement group_id="O3" value="0.5" spread="4.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 11 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="19"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="4.47"/>
                    <measurement group_id="O2" value="-0.5" spread="4.65"/>
                    <measurement group_id="O3" value="-4.5" spread="7.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 12 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="4.93"/>
                    <measurement group_id="O2" value="-1.1" spread="4.61"/>
                    <measurement group_id="O3" value="-4.5" spread="9.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="6.76"/>
                    <measurement group_id="O2" value="-3.2" spread="5.34"/>
                    <measurement group_id="O3" value="-8.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 14 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="5.22"/>
                    <measurement group_id="O2" value="-4.0" spread="5.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 15 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="6.85"/>
                    <measurement group_id="O2" value="-1.5" spread="4.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="4.02"/>
                    <measurement group_id="O2" value="-0.7" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 17 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.7" spread="5.51"/>
                    <measurement group_id="O2" value="-0.7" spread="4.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 18 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                    <measurement group_id="O2" value="-3.0" spread="4.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 19 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                    <measurement group_id="O2" value="-6.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 20 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                    <measurement group_id="O2" value="-5.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 21 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.0"/>
                    <measurement group_id="O2" value="-5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 22 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-12.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 23 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-9.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="4.84"/>
                    <measurement group_id="O2" value="-2.2" spread="5.14"/>
                    <measurement group_id="O3" value="-3.1" spread="6.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Day Follow Up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="6.44"/>
                    <measurement group_id="O2" value="-0.8" spread="5.42"/>
                    <measurement group_id="O3" value="-4.2" spread="6.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Change From Baseline in the EuroQol-5D-5L (EQ-5D-5L) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet</title>
        <description>The EQ-5D-5L contains 1 item for each of 5 dimensions of health-related QoL (i.e., mobility, self-care, usual activities, pain or discomfort and anxiety or depression). Response options for each item varied from having no problems to moderate problems or extreme problems. The EQ-5D-5L (v4.0) is a standardized measure of health utility that provides a single index value for one's health status. The EQ-5D-5L is frequently used for economic evaluations of health care and has been recognized as a valid and reliable instrument for this purpose. The EQ visual analog scale (VAS) is a score that is directly reported by the patient and ranges from 0 to 100 (higher is better quality health).</description>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Doublet Arm</title>
            <description>Encorafenib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O3">
            <title>Phase 3:Control Arm</title>
            <description>Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.&#xD;
Cetuximab: Standard of care.&#xD;
Irinotecan: Standard of care.&#xD;
Folinic Acid: Standard of care.&#xD;
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Change From Baseline in the EuroQol-5D-5L (EQ-5D-5L) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet</title>
          <description>The EQ-5D-5L contains 1 item for each of 5 dimensions of health-related QoL (i.e., mobility, self-care, usual activities, pain or discomfort and anxiety or depression). Response options for each item varied from having no problems to moderate problems or extreme problems. The EQ-5D-5L (v4.0) is a standardized measure of health utility that provides a single index value for one's health status. The EQ-5D-5L is frequently used for economic evaluations of health care and has been recognized as a valid and reliable instrument for this purpose. The EQ visual analog scale (VAS) is a score that is directly reported by the patient and ranges from 0 to 100 (higher is better quality health).</description>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="203"/>
                    <count group_id="O3" value="199"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.0" spread="19.03"/>
                    <measurement group_id="O2" value="66.5" spread="19.51"/>
                    <measurement group_id="O3" value="68.3" spread="19.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="10.89"/>
                    <measurement group_id="O2" value="-0.9" spread="14.09"/>
                    <measurement group_id="O3" value="-2.1" spread="15.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="183"/>
                    <count group_id="O2" value="181"/>
                    <count group_id="O3" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="14.74"/>
                    <measurement group_id="O2" value="1.9" spread="14.81"/>
                    <measurement group_id="O3" value="-2.4" spread="17.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="150"/>
                    <count group_id="O2" value="141"/>
                    <count group_id="O3" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="13.94"/>
                    <measurement group_id="O2" value="4.2" spread="17.32"/>
                    <measurement group_id="O3" value="-1.4" spread="17.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="118"/>
                    <count group_id="O2" value="105"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="13.06"/>
                    <measurement group_id="O2" value="5.6" spread="14.87"/>
                    <measurement group_id="O3" value="-0.4" spread="15.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="99"/>
                    <count group_id="O2" value="80"/>
                    <count group_id="O3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="14.66"/>
                    <measurement group_id="O2" value="5.1" spread="15.11"/>
                    <measurement group_id="O3" value="2.5" spread="11.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="13.33"/>
                    <measurement group_id="O2" value="2.9" spread="16.84"/>
                    <measurement group_id="O3" value="-3.6" spread="13.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="13.64"/>
                    <measurement group_id="O2" value="3.6" spread="16.71"/>
                    <measurement group_id="O3" value="2.4" spread="7.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="10.77"/>
                    <measurement group_id="O2" value="2.0" spread="16.11"/>
                    <measurement group_id="O3" value="-2.8" spread="12.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="15.16"/>
                    <measurement group_id="O2" value="-4.0" spread="12.99"/>
                    <measurement group_id="O3" value="-8.1" spread="8.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="13.34"/>
                    <measurement group_id="O2" value="-8.1" spread="13.68"/>
                    <measurement group_id="O3" value="-1.8" spread="2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 11 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="13.87"/>
                    <measurement group_id="O2" value="-0.1" spread="10.15"/>
                    <measurement group_id="O3" value="4.0" spread="8.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 12 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="20.11"/>
                    <measurement group_id="O2" value="-0.6" spread="11.67"/>
                    <measurement group_id="O3" value="1.5" spread="12.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="17.17"/>
                    <measurement group_id="O2" value="-4.1" spread="14.41"/>
                    <measurement group_id="O3" value="-2.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 14 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="18.06"/>
                    <measurement group_id="O2" value="-0.4" spread="13.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 15 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="14.67"/>
                    <measurement group_id="O2" value="4.2" spread="7.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.4" spread="24.87"/>
                    <measurement group_id="O2" value="3.3" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 17 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.3" spread="20.21"/>
                    <measurement group_id="O2" value="1.7" spread="5.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 18 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                    <measurement group_id="O2" value="-3.3" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 19 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                    <measurement group_id="O2" value="-5.5" spread="13.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 20 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                    <measurement group_id="O2" value="2.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 21 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                    <measurement group_id="O2" value="-5.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 22 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-5.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 23 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-5.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.5" spread="17.40"/>
                    <measurement group_id="O2" value="-8.0" spread="18.99"/>
                    <measurement group_id="O3" value="-12.7" spread="21.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Day Follow Up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.1" spread="20.23"/>
                    <measurement group_id="O2" value="-5.9" spread="20.18"/>
                    <measurement group_id="O3" value="-11.0" spread="17.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Change From Baseline in the Patient Global Impression of Change (PGIC) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet</title>
        <description>The PGIC is a measure of patients' perceptions of change in their symptoms over time that can be used as an anchoring method to determine the minimal clinically important difference for other patient reported outcome (PROs). For this assessment, patients answered the following question: &quot;Since starting treatment, my colorectal cancer symptoms are: (1) very much improved, (2) much improved, (3) minimally improved, (4) no change, (5) minimally worse, (6) much worse or (7) very much worse.&quot;</description>
        <time_frame>Duration of Phase 3, approximately 6 months (up to 28 days per cycle)</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Phase 3:Doublet Arm</title>
            <description>Encorafenib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
          <group group_id="O3">
            <title>Phase 3:Control Arm</title>
            <description>Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.&#xD;
Cetuximab: Standard of care.&#xD;
Irinotecan: Standard of care.&#xD;
Folinic Acid: Standard of care.&#xD;
5-Fluorouracil: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Change From Baseline in the Patient Global Impression of Change (PGIC) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet</title>
          <description>The PGIC is a measure of patients' perceptions of change in their symptoms over time that can be used as an anchoring method to determine the minimal clinically important difference for other patient reported outcome (PROs). For this assessment, patients answered the following question: &quot;Since starting treatment, my colorectal cancer symptoms are: (1) very much improved, (2) much improved, (3) minimally improved, (4) no change, (5) minimally worse, (6) much worse or (7) very much worse.&quot;</description>
          <population>The Full Analysis Set (FAS) consisted of all patients who received at least 1 dose of study drug and had at least 1 post-treatment assessment, which may have included death. The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 patients.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="220"/>
                <count group_id="O3" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="153"/>
                    <count group_id="O2" value="152"/>
                    <count group_id="O3" value="149"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="1.30"/>
                    <measurement group_id="O2" value="3.8" spread="1.30"/>
                    <measurement group_id="O3" value="3.9" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.93"/>
                    <measurement group_id="O2" value="0.1" spread="1.21"/>
                    <measurement group_id="O3" value="0.0" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="130"/>
                    <count group_id="O3" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="1.44"/>
                    <measurement group_id="O2" value="-0.8" spread="1.60"/>
                    <measurement group_id="O3" value="-0.3" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 3 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="105"/>
                    <count group_id="O3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.44"/>
                    <measurement group_id="O2" value="-1.2" spread="1.53"/>
                    <measurement group_id="O3" value="-0.5" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="79"/>
                    <count group_id="O3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.49"/>
                    <measurement group_id="O2" value="-1.1" spread="1.68"/>
                    <measurement group_id="O3" value="-0.5" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 5 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.61"/>
                    <measurement group_id="O2" value="-1.1" spread="1.69"/>
                    <measurement group_id="O3" value="-0.7" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 6 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="1.31"/>
                    <measurement group_id="O2" value="-1.2" spread="1.70"/>
                    <measurement group_id="O3" value="-0.8" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 7 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="1.44"/>
                    <measurement group_id="O2" value="-1.0" spread="1.61"/>
                    <measurement group_id="O3" value="-1.1" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 8 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="1.56"/>
                    <measurement group_id="O2" value="-1.1" spread="1.58"/>
                    <measurement group_id="O3" value="-1.0" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 9 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="1.26"/>
                    <measurement group_id="O2" value="-0.9" spread="1.37"/>
                    <measurement group_id="O3" value="-1.0" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 10 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="1.51"/>
                    <measurement group_id="O2" value="-0.6" spread="1.28"/>
                    <measurement group_id="O3" value="-0.3" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 11 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.38"/>
                    <measurement group_id="O2" value="-1.1" spread="1.38"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 12 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.45"/>
                    <measurement group_id="O2" value="-0.8" spread="1.36"/>
                    <measurement group_id="O3" value="-0.5" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 13 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="1.39"/>
                    <measurement group_id="O2" value="-0.9" spread="1.52"/>
                    <measurement group_id="O3" value="-1.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 14 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="1.46"/>
                    <measurement group_id="O2" value="-1.5" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 15 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="1.47"/>
                    <measurement group_id="O2" value="-1.6" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 16 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="0.82"/>
                    <measurement group_id="O2" value="-0.7" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 17 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="1.53"/>
                    <measurement group_id="O2" value="-1.0" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 18 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                    <measurement group_id="O2" value="-1.0" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 19 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                    <measurement group_id="O2" value="-0.5" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 20 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                    <measurement group_id="O2" value="-2.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 21 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                    <measurement group_id="O2" value="-2.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 22 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-2.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 23 Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="-2.0" spread="NA">Number analyzed is 1 so SD is not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="1.85"/>
                    <measurement group_id="O2" value="0.1" spread="1.82"/>
                    <measurement group_id="O3" value="0.4" spread="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 Day Follow Up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="2.08"/>
                    <measurement group_id="O2" value="0.5" spread="1.43"/>
                    <measurement group_id="O3" value="0.7" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Evaluation of the Area Under the Concentration-time Curve (AUC) for Cetuximab</title>
        <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
        <population>The pharmacokinetics (PK) set included all patients in the Safety Set who had at least 1 post-dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Evaluation of the Area Under the Concentration-time Curve (AUC) for Cetuximab</title>
          <population>The pharmacokinetics (PK) set included all patients in the Safety Set who had at least 1 post-dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
          <units>ng/mL*h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="841000" spread="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="970000" spread="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Evaluation of the Area Under the Concentration-time Curve (AUC) for Encorafenib</title>
        <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
        <population>The PK set included all patients in the Safety Set who had at least 1 post-dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Evaluation of the Area Under the Concentration-time Curve (AUC) for Encorafenib</title>
          <population>The PK set included all patients in the Safety Set who had at least 1 post-dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
          <units>ng/mL*h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11300" spread="61.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6660" spread="61.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Evaluation of the Area Under the Concentration-time Curve (AUC) for Binimetinib</title>
        <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
        <population>The PK set included all patients in the Safety Set who had at least 1 post-dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Evaluation of the Area Under the Concentration-time Curve (AUC) for Binimetinib</title>
          <population>The PK set included all patients in the Safety Set who had at least 1 post-dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
          <units>ng/mL*h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1960" spread="43.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1540" spread="44.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Evaluation of the Area Under the Concentration-time Curve (AUC) for Metabolite of Binimetinib (AR00426032)</title>
        <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
        <population>The PK set included all patients in the Safety Set who had at least 1 post-dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Evaluation of the Area Under the Concentration-time Curve (AUC) for Metabolite of Binimetinib (AR00426032)</title>
          <population>The PK set included all patients in the Safety Set who had at least 1 post-dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
          <units>ng/mL*h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206" spread="46.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0" spread="95.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Cetuximab</title>
        <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
        <population>The PK set included all patients in the Safety Set who had at least 1 post-dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Cetuximab</title>
          <population>The PK set included all patients in the Safety Set who had at least 1 post-dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195000" spread="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199000" spread="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Encorafenib</title>
        <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
        <population>The PK set included all patients in the Safety Set who had at least 1 post-dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Encorafenib</title>
          <population>The PK set included all patients in the Safety Set who had at least 1 post-dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3360" spread="65.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2490" spread="75.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Binimetinib</title>
        <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
        <population>The PK set included all patients in the Safety Set who had at least 1 post-dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Binimetinib</title>
          <population>The PK set included all patients in the Safety Set who had at least 1 post-dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="654" spread="50.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="524" spread="70.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Metabolite of Binimetinib (AR00426032)</title>
        <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
        <population>The PK set included all patients in the Safety Set who had at least 1 post-dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Metabolite of Binimetinib (AR00426032)</title>
          <population>The PK set included all patients in the Safety Set who had at least 1 post-dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.9" spread="50.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5" spread="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Cetuximab</title>
        <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
        <population>The PK set included all patients in the Safety Set who had at least 1 post-dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Cetuximab</title>
          <population>The PK set included all patients in the Safety Set who had at least 1 post-dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.77" lower_limit="1.83" upper_limit="6.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.05" lower_limit="1.00" upper_limit="6.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Encorafenib</title>
        <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
        <population>The PK set included all patients in the Safety Set who had at least 1 post-dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Encorafenib</title>
          <population>The PK set included all patients in the Safety Set who had at least 1 post-dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit=".883" upper_limit="6.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit=".950" upper_limit="5.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Binimetinib</title>
        <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
        <population>The PK set included all patients in the Safety Set who had at least 1 post-dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Binimetinib</title>
          <population>The PK set included all patients in the Safety Set who had at least 1 post-dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" lower_limit=".883" upper_limit="5.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" lower_limit=".900" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Metabolite of Binimetinib (AR00426032)</title>
        <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
        <population>The PK set included all patients in the Safety Set who had at least 1 post-dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Metabolite of Binimetinib (AR00426032)</title>
          <population>The PK set included all patients in the Safety Set who had at least 1 post-dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit=".833" upper_limit="5.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" lower_limit=".933" upper_limit="6.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Evaluation of the Steady-state Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for Binimetinib</title>
        <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
        <population>The PK set included all patients in the Safety Set who had at least 1 post-dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Evaluation of the Steady-state Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for Binimetinib</title>
          <population>The PK set included all patients in the Safety Set who had at least 1 post-dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.3" spread="61.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Evaluation of the Steady-state Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for Encorafenib</title>
        <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
        <population>The PK set included all patients in the Safety Set who had at least 1 post-dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Evaluation of the Steady-state Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for Encorafenib</title>
          <population>The PK set included all patients in the Safety Set who had at least 1 post-dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9" spread="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Evaluation of the Steady-state Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for Cetuximab</title>
        <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
        <population>The PK set included all patients in the Safety Set who had at least 1 post-dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Evaluation of the Steady-state Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for Cetuximab</title>
          <population>The PK set included all patients in the Safety Set who had at least 1 post-dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55400" spread="54.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Safety Lead-in) Evaluation of the Steady-state Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for a Metabolite of Binimetinib</title>
        <time_frame>Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2</time_frame>
        <population>The PK set included all patients in the Safety Set who had at least 1 post-dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Safety Lead-in</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>(Safety Lead-in) Evaluation of the Steady-state Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for a Metabolite of Binimetinib</title>
          <population>The PK set included all patients in the Safety Set who had at least 1 post-dose blood collection for PK with associated bioanalytical results. Patients were analyzed according to the actual treatment and dose received.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.41" spread="68.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Evaluation of the Model-Based Oral Clearance (CL/F) for Encorafenib</title>
        <description>The cross-arm CL/F value is based on the theta determined from a population PK analysis. Data for this Outcome Measure are not reported here because as per plan, the analysis includes pooled data from participants enrolled in multiple studies including those who were not enrolled in this study. The NCTID for those studies for which results have not yet been posted include: NCT01719380, NCT01543698, and NCT01436656. An additional study ARRAY-162-105 is not required to register.</description>
        <time_frame>2 and 6 hours post-dose on Day 1 of Cycle 1. Predose and 2 hours post-dose on Day 1 of Cycle 2.</time_frame>
        <population>The analysis set included all patients in the PK set with measurable plasma concentrations of the test drug plus concentrations from subjects from 4 additional clinical studies. Patients were analyzed according to the actual treatment and dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet, Doublet and Control Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib + cetuximab.&#xD;
Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Evaluation of the Model-Based Oral Clearance (CL/F) for Encorafenib</title>
          <description>The cross-arm CL/F value is based on the theta determined from a population PK analysis. Data for this Outcome Measure are not reported here because as per plan, the analysis includes pooled data from participants enrolled in multiple studies including those who were not enrolled in this study. The NCTID for those studies for which results have not yet been posted include: NCT01719380, NCT01543698, and NCT01436656. An additional study ARRAY-162-105 is not required to register.</description>
          <population>The analysis set included all patients in the PK set with measurable plasma concentrations of the test drug plus concentrations from subjects from 4 additional clinical studies. Patients were analyzed according to the actual treatment and dose received.</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="394"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4" lower_limit="14.9" upper_limit="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Evaluation of the Model-Based Oral Clearance (CL/F) for Binimetinib</title>
        <description>The cross-arm CL/F value is based on the theta determined from a population PK analysis. Data for this Outcome Measure are not reported here because as per plan, the analysis includes pooled data from participants enrolled in multiple studies including those who were not enrolled in this study. The NCTID for those studies for which results have not yet been posted include: NCT01719380, NCT01543698, and NCT01436656. An additional study ARRAY-162-105 is not required to register.</description>
        <time_frame>2 and 6 hours post-dose on Day 1 of Cycle 1. Predose and 2 hours post-dose on Day 1 of Cycle 2.</time_frame>
        <population>The analysis set included all patients in the PK set with measurable plasma concentrations of the test drug plus concentrations from subjects from 4 additional clinical studies. Patients were analyzed according to the actual treatment and dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet, Doublet and Control Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib + cetuximab.&#xD;
Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Evaluation of the Model-Based Oral Clearance (CL/F) for Binimetinib</title>
          <description>The cross-arm CL/F value is based on the theta determined from a population PK analysis. Data for this Outcome Measure are not reported here because as per plan, the analysis includes pooled data from participants enrolled in multiple studies including those who were not enrolled in this study. The NCTID for those studies for which results have not yet been posted include: NCT01719380, NCT01543698, and NCT01436656. An additional study ARRAY-162-105 is not required to register.</description>
          <population>The analysis set included all patients in the PK set with measurable plasma concentrations of the test drug plus concentrations from subjects from 4 additional clinical studies. Patients were analyzed according to the actual treatment and dose received.</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" lower_limit="17.7" upper_limit="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(Phase 3) Evaluation of the Model-Based Clearance (CL) for Cetuximab</title>
        <description>The cross-arm CL/F value is based on the theta determined from a population PK analysis. Data for this Outcome Measure are not reported here because as per plan, the analysis includes pooled data from participants enrolled in multiple studies including those who were not enrolled in this study. The NCTID for those studies for which results have not yet been posted include: NCT01719380, NCT01543698, and NCT01436656. An additional study ARRAY-162-105 is not required to register.</description>
        <time_frame>2 and 6 hours post-dose on Day 1 of Cycle 1. Predose and 2 hours post-dose on Day 1 of Cycle 2.</time_frame>
        <population>The analysis set included all patients in the PK set with measurable plasma concentrations of the test drug plus concentrations from subjects from 4 additional clinical studies. Patients were analyzed according to the actual treatment and dose received.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 3: Triplet, Doublet and Control Arm</title>
            <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib + cetuximab.&#xD;
Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.</description>
          </group>
        </group_list>
        <measure>
          <title>(Phase 3) Evaluation of the Model-Based Clearance (CL) for Cetuximab</title>
          <description>The cross-arm CL/F value is based on the theta determined from a population PK analysis. Data for this Outcome Measure are not reported here because as per plan, the analysis includes pooled data from participants enrolled in multiple studies including those who were not enrolled in this study. The NCTID for those studies for which results have not yet been posted include: NCT01719380, NCT01543698, and NCT01436656. An additional study ARRAY-162-105 is not required to register.</description>
          <population>The analysis set included all patients in the PK set with measurable plasma concentrations of the test drug plus concentrations from subjects from 4 additional clinical studies. Patients were analyzed according to the actual treatment and dose received.</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0154" lower_limit="0.0114" upper_limit="0.0225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AE) were collected during the study (duration of safety lead-in and phase 3,approximately 12 months (up to 28 days per cycle)), which began in 09Oct2016 and still ongoing.</time_frame>
      <desc>An AE is defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occur after patient's signed informed consent has been obtained.</desc>
      <group_list>
        <group group_id="E1">
          <title>Combined Safety Lead-in</title>
          <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
        </group>
        <group group_id="E2">
          <title>Phase 3: Triplet Arm</title>
          <description>Encorafenib + binimetinib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Binimetinib: Orally, twice daily.&#xD;
Cetuximab: Standard of care.</description>
        </group>
        <group group_id="E3">
          <title>Phase 3: Doublet Arm</title>
          <description>Encorafenib + cetuximab.&#xD;
Encorafenib: Orally, once daily.&#xD;
Cetuximab: Standard of care.</description>
        </group>
        <group group_id="E4">
          <title>Phase 3:Control Arm</title>
          <description>Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.&#xD;
Cetuximab: Standard of care.&#xD;
Irinotecan: Standard of care.&#xD;
Folinic Acid: Standard of care.&#xD;
5-Fluorouracil: Standard of care.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="71" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="71" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Infusion-related reaction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Gastrointestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Abdominal distention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Duodenal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Gastrointtestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pancreatitis relapsing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Rectal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Rectal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Large intestine ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Abdominal wall abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Biliary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Cholangitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Gastrintestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Wound abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Bacteria sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colorectal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="217" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="212" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="188" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="137" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="93" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="74" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="80" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="56" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Blood creatine increased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>White blood cell count decrease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PPE syndrome</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumour Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Rhinnorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="76" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Palmar-planar erythrodysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="216"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of the sponsor's agreements with its investigators may vary. However, the sponsor does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e., data from all sites) in the clinical trials.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Pfizer</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

